NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For
the Three Months Ended March 31, 2021 and 2020
(unaudited)
Note
1 – Organization and Summary of Significant Accounting Policies
Description
of Business
Rennova
Health, Inc. (“Rennova”, together with its subsidiaries, the “Company”, “we”, “us” or
“our”) is a provider of health care services. In late 2016, the Company decided to pursue the opportunity to acquire and
operate clusters of rural hospitals and is currently focused on implementing this business model. The Company now owns one operating
hospital in Tennessee, a hospital located in Tennessee that it plans to reopen and operate, a physician’s office in Tennessee and
a rural clinic in Kentucky. Its hospital located in the Jellico, Tennessee closed on March 1, 2021, as more fully discussed below. The
Company’s operations now consist of only one business segment, Hospital Operations.
Basis
of Presentation
The
accompanying unaudited condensed consolidated financial statements were prepared using generally accepted accounting principles for interim
financial information and the instructions to Form 10-Q and Regulation S-X. Accordingly, these financial statements do not include all
information or notes required by generally accepted accounting principles for annual financial statements and should be read in conjunction
with the consolidated financial statements as filed in the Company’s Annual Report on Form 10-K for the year ended December 31,
2020, filed with the Securities and Exchange Commission on April 15, 2021. In the opinion of management, the unaudited condensed consolidated
financial statements included herein contain all adjustments necessary to present fairly the Company’s consolidated financial position
as of March 31, 2021, and the results of its operations, changes in stockholders’ deficit and cash flows for the three months ended
March 31, 2021 and 2020. Such adjustments are of a normal recurring nature. The results of operations for the three months ended March
31, 2021 may not be indicative of results for the year ending December 31, 2021.
Principles
of Consolidation
The
accompanying unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles
generally accepted in the United States of America (“U.S. GAAP”), include the accounts of Rennova and its wholly-owned subsidiaries.
All intercompany transactions and balances have been eliminated in the consolidation.
Comprehensive
Loss
During
the three months ended March 31, 2021 and 2020, comprehensive loss was equal to the net loss amounts presented in the accompanying unaudited
condensed consolidated statements of operations.
Use
of Estimates
The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements, and the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant
estimates and assumptions include the estimates of fair values of assets acquired and liabilities assumed in business combinations, including
hospital acquisitions, reserves and write-downs related to receivables and inventories, the recoverability of long-lived assets, stock
based compensation, the valuation allowance relating to the Company’s deferred tax assets, valuation of equity and derivative instruments,
deemed dividends and debt discounts, among others. Actual results could differ from those estimates and would impact future results of
operations and cash flows.
Cash
and Cash Equivalents
The
Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents.
The Company had minimal cash equivalents at March 31, 2021 and December 31, 2020.
Reverse
Stock Split
On
May 7, 2020, the holders of a majority of the total voting power of the Company’s securities approved an amendment to the Company’s
Certificate of Incorporation to effect a reverse split of all of the Company’s shares of common stock at a specific ratio within
a range from 1-for-100 to 1-for-10,000, and granted authorization to the Board of Directors to determine in its discretion the specific
ratio and timing of the reverse split on or prior to December 31, 2020. On July 22, 2020, the Company’s Board of Directors approved
an amendment to the Company’s Certificate of Incorporation to effect a 1-for-10,000 reverse stock split effective July 31, 2020
(the “Reverse Stock Split”).
As
a result of the Reverse Stock Split, every 10,000 shares of the Company’s common stock was combined and automatically converted
into one share of the Company’s common stock on July 31, 2020. In addition, the conversion and exercise prices of all of the Company’s
outstanding preferred stock, common stock purchase warrants, stock options and convertible debentures were proportionately adjusted at
the applicable reverse split ratio in accordance with the terms of such instruments. In addition, proportionate voting rights and other
rights of common stockholders were not affected by the Reverse Stock Split, other than as a result of the payment of cash in lieu of
fractional shares as no fractional shares were issued in connection with the Reverse Stock Split.
All
share, per share and capital stock amounts and common stock equivalents presented herein have been restated where appropriate to give
effect to the Reverse Stock Split.
The
Company is seeking approval to effect an additional reverse stock split of its common stock as more fully discussed in Notes 2 and 16.
Revenue
Recognition
We
recognize revenue in accordance with Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers
(Topic 606),” including subsequently issued updates. This series of comprehensive guidance has replaced all existing revenue
recognition guidance. There is a five-step approach outlined in the standard. In determining revenue, we first identify the contract
according to the scope of ASU Topic 606 with the following criteria:
|
●
|
The
parties have approved the contract either in writing; orally by acknowledgement; or implicitly, based on customary business practices.
|
|
●
|
Each
party’s rights and the contract’s payment terms are identified.
|
|
●
|
The
contract has commercial substance.
|
|
●
|
Collection
is probable.
|
We
review our calculations for the realizability of gross service revenues monthly to make certain that we are properly allowing for the
uncollectable portion of our gross billings and that our estimates remain sensitive to variances and changes within our payer groups.
The contractual allowance calculation is made based on historical allowance rates for the various specific payer groups monthly with
a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions.
This calculation is routinely analyzed by us based on actual allowances issued by payers and the actual payments made to determine what
adjustments, if any, are needed.
Our
revenues generally relate to contracts with patients in which our performance obligations are to provide health care services to the
patients. Revenues are recorded during the period our obligations to provide health care services are satisfied. Our performance obligations
for inpatient services are generally satisfied over periods that average approximately five days, and revenues are recognized based on
charges incurred in relation to total expected charges. Our performance obligations for outpatient services are generally satisfied over
a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare,
Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges)
and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with
(managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers
for the services we provide to the related patients typically specify payments at amounts less than our standard charges. Medicare generally
pays for inpatient and outpatient services at prospectively determined rates based on clinical, diagnostic and other factors. Services
provided to patients having Medicaid coverage are generally paid at prospectively determined rates per discharge, per identified service
or per covered member. Agreements with commercial insurance carriers, managed care and preferred provider organizations generally provide
for payments based upon predetermined rates per diagnosis, per diem rates or discounted fee-for-service rates. Management continually
reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed
care contractual terms resulting from contract renegotiations and renewals. Our revenues are based upon the estimated amounts we expect
to be entitled to receive from patients and third-party payers. Estimates of contractual allowances under managed care and commercial
insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients
and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts
and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience)
related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect.
Laws
and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. Estimated reimbursement amounts
are adjusted in subsequent periods as cost reports are prepared and filed and as final settlements are determined (in relation to certain
government programs, primarily Medicare, this is generally referred to as the “cost report” filing and settlement process).
There were no adjustments to estimated Medicare and Medicaid reimbursement amounts and disproportionate-share funds related primarily
to cost reports filed during the three months ended March 31, 2021 and 2020.
The
Emergency Medical Treatment and Labor Act (“EMTALA”) requires any hospital participating in the Medicare program to conduct
an appropriate medical screening examination of every person who presents to the hospital’s emergency room for treatment and, if
the individual is suffering from an emergency medical condition, to either stabilize the condition or make an appropriate transfer of
the individual to a facility able to handle the condition. The obligation to screen and stabilize emergency medical conditions exists
regardless of an individual’s ability to pay for treatment. Federal and state laws and regulations require, and our commitment
to providing quality patient care encourages, us to provide services to patients who are financially unable to pay for the health care
services they receive. The federal poverty level is established by the federal government and is based on income and family size. The
Company considers the poverty level in determining whether patients qualify for free or reduced cost of care. Because we do not pursue
collection of amounts determined to qualify as charity care, they are not reported in revenues. We provide discounts to uninsured patients
who do not qualify for Medicaid or charity care. In implementing the uninsured discount policy, we may first attempt to provide assistance
to uninsured patients to help determine whether they may qualify for Medicaid, other federal or state assistance, or charity care. If
an uninsured patient does not qualify for these programs, the uninsured discount is applied.
The
collection of outstanding receivables for Medicare, Medicaid, managed care payers, other third-party payers and patients is our
primary source of cash and is critical to our operating performance. The primary collection risks relate to uninsured patient
accounts, including patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable agreement,
but patient responsibility amounts (deductibles and copayments) remain outstanding. Implicit price concessions relate primarily
to amounts due directly from patients. Estimated implicit price concessions are recorded for all uninsured accounts, regardless
of the aging of those accounts. Accounts are written off when all reasonable internal and external collection efforts have been
performed. The estimates for implicit price concessions are based upon management’s assessment of historical write offs
and expected net collections, business and economic conditions, trends in federal, state and private employer health care coverage
and other collection indicators. Management relies on the results of detailed reviews of historical write-offs and collections
at facilities that represent a majority of our revenues and accounts receivable (the “hindsight analysis”) as a primary
source of information in estimating the collectability of our accounts receivable. We perform the hindsight analysis quarterly,
utilizing rolling twelve-months accounts receivable collection and write off data. We believe our quarterly updates to the estimated
contractual allowance amounts and to the estimated implicit price concessions at each of our hospital facilities provide
reasonable estimates of our revenues and valuations of our accounts receivable. At March 31, 2021 and 2020, estimated contractual
allowances of $5.5 million and $10.5 million, respectively, and estimated implicit price concessions of $3.0 million and
$1.4 million, respectively, have been recorded as to enable us to record our revenues and accounts receivable at the estimated
amounts we expect to collect. The estimated accounts receivable collection rate has been reduced to a lower percentage of gross
revenue due to serving only emergency room patients during the three months ended March 31, 2021. Inpatient services typically
deliver higher collection rates and the absence of inpatient services in the first quarter meant that the Company was dependent
on revenue from emergency room services, which is typically a lower percentage of gross revenue. Inpatient services reopened in
May
To
quantify the total impact of the trends related to uninsured accounts, we believe it is beneficial to view total uncompensated care,
which is comprised of charity care, uninsured discounts and implicit price concessions. Total uncompensated care as a percentage of gross
revenues was 9.5% and 10% for the three months ended March 31, 2021 and 2020, respectively.
Contractual
Allowances and Doubtful Accounts Policy
Accounts
receivable are reported at realizable value, net of allowances for credits and doubtful accounts, which are estimated and recorded
in the period the related revenue is recorded. The Company has a standardized approach to estimating and reviewing the collectability
of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer
reimbursement experience is an integral part of the estimation process related to allowances for contractual credits and doubtful
accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues which may
impact the collectability of these receivables or reserve estimates. Receivables deemed to be uncollectible are charged against
the allowance for doubtful accounts at the time such receivables are written-off. Recoveries of receivables previously written-off
are recorded as credits to the allowance for doubtful accounts. Revisions to the allowances for doubtful accounts estimates are
recorded as an adjustment to revenues. As required by Topic 606, for the three months ended March 31, 2021 and 2020, after
estimated implicit price concessions and contractual and related allowance adjustments to revenues of $8.5 million and
$11.9 million, respectively, we reported negative net revenues of $0.7 million and positive net revenues of $1.8 million, respectively.
We continue to review the provision for implicit price concessions and contractual and related contractual allowances.
See Note 4 – Accounts Receivable.
Leases
in Accordance with ASU No. 2016-02
We
account for leases in accordance with ASU No. 2016-02, Leases (Topic 842), which requires leases with durations greater than 12
months to be recognized on the balance sheet. Upon adoption in 2019, we elected the package of transition provisions available which
allowed us to carryforward our historical assessments of (1) whether contracts are or contain leases, (2) lease classification and (3)
initial direct costs. We lease property and equipment under finance and operating leases. For leases with terms greater than 12 months,
we record the related right-of-use assets and right-of-use obligations at the present value of lease payments over the term. We do not
separate lease and non-lease components of contracts. Our operating and finance leases are more fully discussed in Note 9.
Impairment
or Disposal of Long-Lived Assets
We
account for the impairment or disposal of long-lived assets according to the Financial Accounting Standards Board (the “FASB”)
Accounting Standards Codification (“ASC”) Topic 360, Property, Plant and Equipment (“ASC 360”). ASC 360
clarifies the accounting for the impairment of long-lived assets and for long-lived assets to be disposed of, including the disposal
of business segments and major lines of business. Long-lived assets are reviewed when facts and circumstances indicate that the carrying
value of the asset may not be recoverable. When necessary, impaired assets are written down to estimated fair value based on the best
information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future
cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could
vary significantly from such estimates. The Company did not record an asset impairment charge during the three months ended March 31,
2021 and 2020.
Derivative
Financial Instruments and Fair Value, Including the Adoption of ASU 2017-11
In
July 2017, the FASB issued ASU 2017-11 “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives
and Hedging (Topic 815).” The amendments in Part I of this Update change the classification analysis of certain equity-linked financial
instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified
as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument
is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments.
As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a
derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial
instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect
of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common
stockholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to
the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other
Options), including related EPS guidance (in Topic 260).
When
the down round feature is included in an equity-classified freestanding financial instrument, the value of the effect of the down round
feature is treated as a dividend when it is triggered and as a numerator adjustment in the EPS calculation. This reflects the occurrence
of an economic transfer of value to the holder of the instrument, while alleviating the complexity and income statement volatility associated
with fair value measurement on an ongoing basis. The incremental value of warrants as a result of the down round provisions of $50.4
million were recorded as deemed dividends for the three months ended March 31, 2021. We did not record deemed dividends for the three
months ended March 31, 2020. See Note 10 for an additional discussion of derivative financial instruments.
Income
Taxes
Income
taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities
and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial
statement carrying amounts of assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using
enacted or substantially enacted income tax rates expected to apply when the asset is realized or the liability settled. The effect of
a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs.
Future income tax assets are recognized to the extent that they are considered more likely than not to be realized. When projected future
taxable income is insufficient to provide for the realization of deferred tax assets, the Company recognizes a valuation allowance.
In
accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be sustained
upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the
technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than
fifty percent likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in
the Company recording a tax liability that would reduce net assets. Based on its analysis, the Company has determined that it has not
incurred any liability for unrecognized tax benefits as of March 31, 2021 and 2020.
Earnings
(Loss) Per Share
The
Company reports earnings (loss) per share in accordance with ASC Topic 260, “Earnings Per Share,” which establishes standards
for computing and presenting earnings per share. Basic earnings (loss) per share of common stock is calculated by dividing net earnings
(loss) allocable to common stockholders by the weighted-average shares of common stock outstanding during the period, without consideration
of common stock equivalents. Diluted earnings (loss) per share is calculated by adjusting the weighted-average shares of common stock
outstanding for the dilutive effect of common stock equivalents, including stock options and warrants outstanding for the period as determined
using the treasury stock method. For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from
the calculation when their effect would be anti-dilutive. Therefore, basic and diluted net loss per share applicable to common stockholders
is the same for periods with a net loss. See Note 3 for the computation of loss per share for the three months ended March 31, 2021 and
2020.
Note
2 – Liquidity and Financial Condition
Jamestown
Regional Medical Center Medicare Agreement
Following
an inspection at Jamestown Regional Medical Center on February 5, 2019, the hospital was informed on February 15, 2019 that several conditions
of participation in its Medicare agreement were deficient. The hospital was informed that if the deficiencies were not corrected by May
16, 2019 the Medicare agreement would terminate. A follow-up inspection on May 15, 2019 resulted in the determination that the hospital
had failed to adequately correct the deficiencies highlighted and a notice of involuntary termination was issued that was effective on
June 12, 2019. A significant percentage of patients at Jamestown Regional Medical Center are covered by Medicare and without any ability
to get paid for these services the Company suspended operations at the hospital. The Company plans to reopen the hospital upon securing
adequate capital to do so. The reopening plans have also been disrupted by the coronavirus (“COVID-19”) pandemic and the
timing of the reopening has been delayed and is now intended that the re-opening process will be initiated in mid-2021.
Jellico
Community Hospital and CarePlus Center
Effective
March 5, 2019, the Company acquired certain assets related to Jellico Community Hospital and CarePlus Center. Jellico Community Hospital
was a 54-bed acute care facility that offered comprehensive services, including diagnostic imaging, radiology, surgery (general, gynecological
and vascular), nuclear medicine, wound care and hyperbaric medicine, intensive care, emergency care and physical therapy. The CarePlus
Center services include diagnostic imaging services, x-ray, mammography, bone densitometry, computed tomography (CT), ultrasound, physical
therapy and laboratory services on a walk-in basis. On March 1, 2021, the Company closed Jellico Community Hospital, after the city of
Jellico issued a 30-day termination notice for the lease of the building. The Company does not expect this closure to have an adverse
effect on its business strategy and believes it will have a positive impact from a reduced cash requirement in the immediate future.
Impact
of the Pandemic
COVID-19
was declared a global pandemic by the World Health Organization on March 11, 2020. We have been closely monitoring the COVID-19 pandemic
and its impact on our operations and we have taken steps intended to minimize the risk to our employees and patients. These steps have
increased our costs and our revenues have been significantly adversely affected. Demand for hospital services has substantially decreased.
As more fully discussed in Note 6, we have received Paycheck Protection Program (“PPP”) loans. We have also received Health
and Human Services (“HHS”) Provider Relief Funds from the federal government as more fully discussed below. If the COVID-19
pandemic continues for a further extended period, we expect to incur significant losses and additional financial assistance may be required.
Going forward, the Company is unable to determine the extent to which the COVID-19 pandemic will continue to affect its business. The
nature and effect of the COVID-19 pandemic on our balance sheet and results of operations will depend on the severity and length of the
pandemic in our service areas; government activities to mitigate the pandemic’s effect; regulatory changes in response to the pandemic,
especially those affecting rural hospitals; and existing and potential government assistance that may be provided.
Hospitalizations
in Tennessee for COVID-19 increased throughout 2020 and appear to have peaked in December 2020. From third party information, there have
been 862,401 cases and 12,441 deaths as of May 29, 2021. The roll out of vaccinations is expected to significantly reduce the risk of
death and reduce transmission of the virus and a return to more normal expectations is expected throughout 2021. These developments have
had, and may continue to have, a material adverse effect on the Company and its hospitals operations.
HHS
Provider Relief Funds
The
Company received Provider Relief Funds from the United States Department of HHS provided to eligible healthcare providers out of the
$100 billion Public Health and Social Services Emergency Fund provided for in the Coronavirus Aid, Relief and Economic Security Act (the
“CARES Act”). The funds were allocated to eligible healthcare providers for expenses and lost revenue attributable to the
COVID-19 pandemic. The funds were being released in tranches, and HHS partnered with UnitedHealth Group to distribute the initial $30
billion in funds by direct deposit to providers. As of March 31, 2021, Company-owned facilities have received approximately $12.5 million
in relief funds. This included approximately $120,000 received by Jamestown Medical Center, Inc. where staff continue to be employed.
The fund payments are grants, not loans, and HHS will not require repayment, but providers are restricted and the funds must be used
only for grant approved purposes. Based on an analysis of the compliance and reporting requirements of the Provider Relief Funds and
the impact of the pandemic on our operating results through March 31, 2021, we recognized $10.5 million of these payments as income of
which $8.0 million was recognized during the second and third quarters of 2020 and $2.5 million was recognized during the three months
ended March 31, 2021. The unrecognized portion has been recorded in accrued liabilities in our condensed consolidated financial statements.
The Company’s assessment of whether the terms and conditions for amounts received have been met considers all frequently asked
questions and other interpretive guidance issued by HHS. On September 19, 2020, HHS issued a Post-Payment Notice of Reporting Requirements
(the “September 19, 2020 Notice”), which indicates that providers may recognize reimbursement for healthcare-related expenses,
as defined therein, attributable to coronavirus that another source has not reimbursed and is not obligated to reimburse. Additionally,
amounts received from the HHS that are not fully expended on eligible healthcare-related expenses may be recognized as reimbursement
for lost revenues, represented as a negative change in year-over-year net patient care operating income. Providers may apply payments
to lost revenues up to the amount of the 2019 net gain from healthcare-related sources or, for entities that reported a negative net
operating gain in 2019, receipts from the HHS may be recognized up to a net zero gain/loss in 2020. On October 22, 2020, HHS issued an
updated Post-Payment Notice of Reporting Requirements and a Reporting Requirements Policy Update (together, the “October 22, 2020
Notice”), which includes two primary changes: (1) the definition of lost revenue is changed to refer to the negative year-over-year
difference in 2019 and 2020 actual revenue from patient care related sources as opposed to the negative year-over-year change in net
patient care operating income, and (2) the definition of reporting entities is broadened to include the parent of one or more subsidiary
tax identification numbers that received general distribution payments, entities having providers associated with it that provide diagnoses,
testing or treatment for cases of COVID-19, or entities that can otherwise attest to the terms and conditions. As codified in the October
22, 2020 Notice, the Company’s estimate of pandemic relief funds as of March 31, 2021 includes the allocation of certain general
funds among subsidiaries. Regarding the amended definition of lost revenues, such change served to increase amounts eligible to be recognized
as income, as compared to the September 19, 2020 Notice. Provider Relief Funds received through HHS that have not yet been recognized
as income or otherwise have not been refunded to HHS as of March 31, 2021, are reflected within accrued liabilities in the condensed
consolidated balance sheets, and such unrecognized amounts may be recognized as income in future periods if the underlying conditions
for recognition are met. As evidenced by the October 22, 2020 Notice, HHS’ interpretation of the underlying terms and conditions
of such payments, including auditing and reporting requirements, continues to evolve. On January 15, 2021, the government issued “General
and Targeted Distribution Post-Payment Notice of Reporting Requirements,” (the “January 15, 2021 Notice”), which again
provides guidance on reporting instructions and use of funds. Additional guidance or new and amended interpretations of existing guidance
on the terms and conditions of such payments may result in changes in the Company’s estimate of amounts for which the terms and
conditions are reasonably assured of being met, and any such changes may be material. Additionally, any such changes may result in the
Company’s inability to recognize additional Provider Relief Fund payments or may result in derecognition of amounts previously
recognized, which (in any such case) may be material.
As
of March 31, 2021, the Company’s estimate of the amount for which it is reasonably assured of meeting the underlying terms and
conditions was updated based on, among other things, the September 19, 2020 Notice, the October 22, 2020 Notice, the January 15, 2021
Notice and the Company’s results of operations during 2020 and the three months ended March 31, 2021. Taking into account these
countervailing factors, the Company believes that the amount recognized as of March 31, 2021 of approximately $10.5 million is an appropriate
estimate.
Proposed
Reverse Stock Split
As
a result of conversions of shares of the Company’s preferred stock, the Company, as of the date of this report, has 10,000,000,000
shares of its common stock issued and outstanding. The Company, therefore, has issued all of its authorized shares of common stock. It
cannot issue additional shares of common stock unless and until it is able to amend its Certificate of Incorporation to increase its
authorized common stock or it effects a reverse stock split. The Company needs immediate additional capital to execute on its business
plan and without the ability to issue shares of common stock will have difficulty securing the capital required to continue in business.
Accordingly, on May 14, 2021, the Company filed a preliminary Information Statement on Schedule 14C to seek approval to effect a reverse
stock split of its common stock. The ratio and timing of the proposed reverse stock split have not yet been determined.
Going
Concern
Under
ASU 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40) ASC 205-40”), the Company has the responsibility
to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they
become due within one year after the date that the financial statements are issued. As required by ASC 205-40, this evaluation shall
initially not take into consideration the potential mitigating effects of plans that have not been fully implemented as of the date the
financial statements are issued. Management has assessed the Company’s ability to continue as a going concern in accordance with
the requirements of ASC 205-40.
As
reflected in the condensed consolidated financial statements, the Company had a working capital deficit and an accumulated deficit of
$60.6 million and $922.8 million, respectively, at March 31, 2021. In addition, the Company had a loss from continuing operations of
approximately $3.7 million and $5.8 million for the three months ended March 31, 2021 and 2020, respectively, and cash used in operating
activities was $1.0 million and $2.5 million for the three months ended March 31, 2021 and 2020, respectively. As of the date of this
report, our cash is deficient and payments for our operations in the ordinary course are not being made. The continued losses and other
related factors, including the payment defaults under the terms of outstanding notes payable and debentures as more discussed in Notes
6 and 7, raise substantial doubt about the Company’s ability to continue as a going concern for twelve months from the filing date
of this report.
The
Company’s condensed consolidated financial statements are prepared assuming the Company can continue as a going concern, which
contemplates continuity of operations through realization of assets, and the settling of liabilities in the normal course of business.
The Company plans to separate out its Advanced Molecular Services Group (“AMSG”) and Health Technology Solutions, Inc. (“HTS”),
as independent publicly traded companies in either a spin off or transaction with a publicly quoted company. In accordance with ASC 205-20
and having met the criteria for “held for sale”, the Company has reflected amounts relating to AMSG and HTS as disposal groups
classified as held for sale and included as part of discontinued operations. AMSG and HTS are no longer included in the segment reporting
following the reclassification to discontinued operations. The discontinued operations of AMSG and HTS are described further in Note
14. In addition, during 2020, the Company announced plans to sell its last clinical laboratory, EPIC Reference Labs, Inc., and as a result,
EPIC Reference Labs, Inc.’s operations have been classified as held for sale and included in discontinued operations for all periods
presented, as more fully discussed in Note 14.
On
March 1, 2021, the Company closed Jellico Community Hospital, after the city of Jellico issued a 30-day termination notice for the lease
of the building. Jellico Community Hospital had been operating at a loss since it was acquired by the Company in March 2019. The Company’s
core operating businesses are now a rural hospital, a physician’s office, CarePlus Center and a hospital that it plans to reopen
and operate. Rural hospitals are a specialized marketplace with a requirement for capable and knowledgeable management. The Company’s
current financial condition may make it difficult to attract and maintain adequate expertise in its management team to successfully operate
these businesses.
There
can be no assurance that the Company will be able to achieve its business plan, which is to acquire and operate clusters of rural hospitals,
raise any additional capital or secure the additional financing necessary to implement its current operating plan. The ability of the
Company to continue as a going concern is dependent upon its ability to raise adequate capital to fund its operations and repay its outstanding
debentures and other past due obligations, fully align its operating costs, increase its revenues, and eventually regain profitable operations.
The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is
unable to continue as a going concern.
Note
3 – Loss Per Share
Basic
loss per share is computed by dividing the loss available to common stockholders by the weighted-average number of shares of common stock
outstanding during the period. Basic loss per share excludes potential dilution of securities or other contracts to issue shares of common
stock. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock
were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company.
For each of the three months ended March 31, 2021 and 2020, basic loss per share is the same as diluted loss per share.
The
following table sets forth the computation of the Company’s basic and diluted net loss per share during the three months ended
March 31, 2021 and 2020:
|
|
Three Months Ended March 31,
|
|
|
|
2021
|
|
|
2020
|
|
Numerator
|
|
|
|
|
|
|
|
|
Net loss from continuing operations
|
|
$
|
(3,667,328
|
)
|
|
$
|
(5,810,709
|
)
|
Deemed dividends
|
|
|
(50,358,149
|
)
|
|
|
-
|
|
Net loss attributable to common stockholders, continuing operations
|
|
$
|
(54,025,477
|
)
|
|
$
|
(5,810,709
|
)
|
Net (loss) income from discontinued operations
|
|
|
(226,666
|
)
|
|
|
18,931
|
|
Net loss available to common stockholders
|
|
$
|
(54,252,143
|
)
|
|
$
|
(5,791,778
|
)
|
|
|
|
|
|
|
|
|
|
Denominator
|
|
|
|
|
|
|
|
|
Basic and diluted weighted average common shares outstanding
|
|
|
248,823,935
|
|
|
|
981,322
|
|
|
|
|
|
|
|
|
|
|
Loss per share, basic and diluted
|
|
|
|
|
|
|
|
|
Basic and diluted, continuing operations
|
|
$
|
(0.22
|
)
|
|
$
|
(5.92
|
)
|
Basic and diluted, discontinued operations
|
|
$
|
(0.00
|
)
|
|
$
|
0.02
|
|
Total basic and diluted
|
|
$
|
(0.22
|
)
|
|
$
|
(5.90
|
)
|
Diluted
loss per share excludes all dilutive potential shares if their effect is anti-dilutive. As of March 31, 2021 and 2020, the following
potential common stock equivalents were excluded from the calculation of diluted loss per share as their effect was anti-dilutive:
|
|
Three Months Ended March 31,
|
|
|
|
2021
|
|
|
2020
|
|
Warrants
|
|
|
13,830,704,953
|
|
|
|
63,458,536
|
|
Convertible preferred stock
|
|
|
10,870,999,619
|
|
|
|
7,887,237
|
|
Convertible debentures
|
|
|
770,100,000
|
|
|
|
3,063,478
|
|
Stock options
|
|
|
26
|
|
|
|
26
|
|
|
|
|
25,471,804,598
|
|
|
|
74,409,277
|
|
The
terms of certain of the warrants, convertible preferred stock and convertible debentures issued by the Company provide for reductions
in the per share exercise prices of the warrants and the per share conversion prices of the debentures and preferred stock (if
applicable and subject to a floor in certain cases), in the event that the Company issues common stock or common stock equivalents
(as that term is defined in the agreements) at an effective exercise/conversion price that is less than the then exercise/conversion
price of the outstanding warrants, preferred stock or debentures, as the case may be. In addition, many of these equity-based
securities contain exercise or conversion prices that vary based upon the price of the Company’s common stock on the date
of exercise/conversion (see Notes 7 and 11). These provisions have resulted in significant dilution of the Company’s common
stock and have given rise to reverse splits of the Company’s common stock. As a result of these down round provisions, the
potential common stock and common stock equivalents totalled 167.4 billion at June 2, 2021, as more fully discussed in
Note 16. See Note 11 regarding a discussion of the number of shares of the Company’s authorized common stock.
Note
4 – Accounts Receivable and Income Tax Refunds Receivable
Accounts
receivables at March 31, 2021 (unaudited) and December 31, 2020 consisted of the following:
|
|
March 31,
|
|
|
December 31,
|
|
|
|
2021
|
|
|
2020
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
$
|
13,544,708
|
|
|
$
|
16,922,576
|
|
Less:
|
|
|
|
|
|
|
|
|
Allowance for contractual obligations
|
|
|
(8,388,166
|
)
|
|
|
(13,185,843
|
)
|
Allowance for implicit price concessions
|
|
|
(4,235,507
|
)
|
|
|
(1,513,827
|
)
|
Accounts receivable owed under sales agreements
|
|
|
(921,035
|
)
|
|
|
(1,723,452
|
)
|
Accounts receivable, net
|
|
$
|
-
|
|
|
$
|
499,454
|
|
The
allowance for contractual obligations reflected in the table above decreased as a percentage of accounts receivable to 62% at March 31,
2021 compared to 78% at December 31, 2020. The allowance is based on historical contractual allowance rates. The decrease in the percentage
of contractual obligations to accounts receivable was due to rate changes.
For
the three months ended March 31, 2021 and 2020, estimated implicit price concessions deducted from revenues were
$3.0 million and $1.4 million, respectively. The allowance for implicit price concessions was $4.2 million at March 31,
2021 compared to $1.5 million at December 31, 2020, an increase of $2.7 million. The increase was due to updates to estimated
collection rates. The Company’s policy is to write off accounts receivable balances against the allowance for implicit
price concessions once an accounts receivable ages past a specified number of days.
Accounts
Receivable Sales Agreements and Installment Promissory Note
During
the year ended December 31, 2020, the Company entered into six accounts receivable sales agreements under which the Company sold $3.3
million of accounts receivable on a non-recourse basis for a purchase price paid to the Company of $2.2 million, less $0.1million of
origination fees. Accordingly, the Company recorded a loss on the sales of $1.2 million during the year ended December 31, 2020. As of
March 31, 2021 and December 31, 2020, $1.6 million and $1.7 million, respectively, was outstanding and owed under the accounts receivable
sales agreements, of which $0.9 million was recorded as a reduction of accounts receivable and $0.7 million was recorded in accrued expenses.
The $0.7 million that was recorded in accrued expenses (see Note 5) represents the portion sold in excess of the balance of accounts
receivable recorded by the Company as due at March 31, 2021.
On
January 29, 2020, the Company entered into a Secured Installment Promissory Note (the “Installment Note”) in the principal
amount of $1.2 million, less $0.1 million in origination fees, the proceeds of which were used to satisfy in full the amounts due under
accounts receivable sales agreements entered into during 2019. The Installment Note is more fully discussed in Note 6.
Income
Tax Refunds Receivable
As
of March 31, 2021 and December 31, 2020, the Company had $1.1 million and $1.4 million, respectively, of income tax refunds receivable.
During 2020, the U.S. Congress approved the CARES Act, which allowed a five-year carryback privilege for federal net operating tax losses
that arose in a tax year beginning in 2018 and through 2020. As a result, during the year ended December 31, 2020, the Company recorded
approximately $1.1 million in refunds from the carryback of certain of its federal net operating losses. In addition, during the year
ended December 31, 2020, the Company recorded $0.3 million in refunds related to other net operating loss carryback adjustments. During
the three months ended March 31, 2021, the Company received income tax refunds of $0.3 million, which represented income tax refunds
associated with the CARES Act. No refunds were received during the three months ended March 31, 2020. The Company used the $0.3 million
of refunds that it received in the three months ended March 31, 2021 to repay a portion of the amount that it owes for federal income
tax liabilities that arose from an audit of the Company’s 2015 Federal tax return as more fully discussed in Note 13. The Company’s
income taxes are more fully discussed in Note 15 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.
Note
5 – Accrued Expenses
Accrued
expenses at March 31, 2021 (unaudited) and December 31, 2020 consisted of the following:
|
|
March 31,
|
|
|
December 31,
|
|
|
|
2021
|
|
|
2020
|
|
Accrued payroll and related liabilities
|
|
$
|
9,059,414
|
|
|
$
|
8,263,940
|
|
HHS Provider Relief Funds
|
|
|
1,909,217
|
|
|
|
4,400,000
|
|
Accrued interest
|
|
|
5,530,997
|
|
|
|
4,728,942
|
|
Accrued legal
|
|
|
1,097,318
|
|
|
|
1,097,318
|
|
Amounts owed under accounts receivable sales agreements in excess of accounts receivable
|
|
|
651,219
|
|
|
|
-
|
|
Other accrued expenses
|
|
|
1,143,959
|
|
|
|
645,369
|
|
Accrued expenses
|
|
$
|
19,392,124
|
|
|
$
|
19,135,569
|
|
Accrued
payroll and related liabilities at March 31, 2021 and December 31, 2020 included approximately $2.6 million and $2.5 million, respectively,
for penalties associated with approximately $4.7 million and $4.4 million of accrued past due payroll taxes as of March 31, 2021 and
December 31, 2020, respectively.
As
of March 31, 2021 and December 31, 2020, we have deferred $1.9 million and $4.4 million, respectively, of HHS Provider Relief funds as
more fully discussed in Note 2.
Amounts
owed under accounts receivable sales agreements of $0.7 million at March 31, 2021 are more fully discussed in Note 4.
Note
6 – Notes Payable
The
Company and its subsidiaries are party to a number of loans with affiliates and unrelated parties. At March 31, 2021 (unaudited) and
December 31, 2020, notes payable consisted of the following:
Notes
Payable – Third Parties
|
|
March 31, 2021
|
|
|
December 31, 2020
|
|
|
|
|
|
|
|
|
Loan payable to TCA Global Master Fund, L.P. (“TCA”) in the original principal amount of $3 million at 16% interest (the “TCA Debenture”). Principal and interest payments due in various installments through December 31, 2017
|
|
$
|
1,741,893
|
|
|
$
|
1,741,893
|
|
|
|
|
|
|
|
|
|
|
Notes payable to CommerceNet and Jay Tenenbaum in the original principal amount of $500,000, bearing interest at 6% per annum (the “Tegal Notes”). Principal and interest payments due annually from July 12, 2015 through July 12, 2017
|
|
|
292,792
|
|
|
|
297,068
|
|
|
|
|
|
|
|
|
|
|
Note payable to Anthony O’Killough dated September 27, 2019 in the original principal amount of $1.9 million. Interest is due only upon event of default. Issued net of $0.3 million of debt discount and $0.1 million of financing fees. Payment due in installments through November 2020.
|
|
|
1,450,000
|
|
|
|
1,450,000
|
|
|
|
|
|
|
|
|
|
|
Notes payable under the Paycheck Protection Program (“PPP) issued on April 20, 2020 through May 1, 2020 bearing interest at a rate of 1% per annum. To the extent not forgiven, principal and interest payments are due monthly beginning sixteen months from the date of issuance and the notes mature 40 months from the date of issuance.
|
|
|
2,385,921
|
|
|
|
2,385,921
|
|
|
|
|
|
|
|
|
|
|
Installment Note payable to Ponte Investments, LLC dated January 29, 2020, less original
issue discount of $0.1 million, non-interest bearing, payable in weekly installment payments ranging from $22,500 to $34,000
due on or before February 5, 2020 through on or before October 21, 2020, the maturity date.
|
|
|
88,350
|
|
|
|
108,350
|
|
|
|
|
|
|
|
|
|
|
Note payable dated January 31, 2021 due six months from the date of issuance bearing interest at 10% for the period outstanding.
|
|
|
185,000
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Note payable dated February 16, 2021 due six months from the date of issuance bearing interest at 10% for the period outstanding.
|
|
|
60,000
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Warrant pre-payment promissory notes dated February 25, 2021, non-interest bearing, $550,000 principal amount, issued with $50,000 of original issue discounts and payable 12 months from the date of issuance
|
|
|
504,795
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,708,751
|
|
|
|
5,983,232
|
|
Less current portion
|
|
|
(5,993,895
|
)
|
|
|
(4,786,976
|
)
|
Notes payable - third parties, net of current portion
|
|
$
|
714,856
|
|
|
$
|
1,196,256
|
|
The
Company did not make the required monthly principal and interest payments due under the TCA Debenture for the period from October 2016
through March 2017. On February 2, 2017, the Company made a payment to TCA in the amount of $0.4 million, which was applied to accrued
and unpaid interest and fees, including default interest, as of the date of payment. On March 21, 2017, the Company made a payment to
TCA in the amount of $0.75 million, of which approximately $0.1 million was applied to accrued and unpaid interest and fees under the
TCA Debenture. Also on March 21, 2017, the Company entered into a letter agreement with TCA, which (i) waived any payment defaults through
March 21, 2017; (ii) provided for the $0.75 million payment discussed above; (iii) set forth a revised repayment schedule whereby the
remaining principal plus interest aggregating to approximately $2.6 million was to be repaid in various monthly installments from April
of 2017 through September of 2017; and (iv) provided for payment of an additional service fee in the amount of $150,000, which was due
on June 27, 2017, the day after the effective date of the registration statement filed by the Company; which amount was reflected in
accrued expenses at March 31, 2021. In addition, TCA entered into an inter-creditor agreement with the purchasers of the convertible
debentures (see Note 7), which sets forth rights, preferences and priorities with respect to the security interests in the Company’s
assets. On September 19, 2017, the Company entered into a new agreement with TCA, which extended the repayment schedule through December
31, 2017. The remaining debt to TCA remains outstanding and TCA has made a demand for payment. In May 2020, the SEC appointed a Receiver
to close down the TCA Global Master Fund, L.P. over allegations of accounting fraud. The amount recorded by the Company as being owed
to TCA was based on TCA’s application of prior payments made by the Company. The Company believes that prior payments of principal
and interest may have been applied to unenforceable investment banking and other fees and charges. It is the Company’s position
that the amount owed to TCA is less than the amount set forth above.
The
Company did not make the second annual principal payment under the Tegal Notes that was due on July 12, 2016. On November 3, 2016, the
Company received a default notice from the holders of the Tegal Notes demanding immediate repayment of the outstanding principal at that
time of $341,612 and accrued interest of $43,000. On December 7, 2016, the Company received a breach of contract complaint with a request
for the entry of a default judgment (see Note 13). On April 23, 2018, the holders of the Tegal Notes received a judgment against the
Company. As of March 31, 2021, the Company has paid $48,820 of principal amount of these notes.
On
September 27, 2019, the Company issued a promissory note to a lender in the principal amount of $1.9 million and received proceeds of
$1.5 million, which was net of a $0.3 million original issue discount and $0.1 million in financing fees. The first principal payment
of $1.0 million was due on November 8, 2019 and the remaining $0.9 million was due on December 26, 2019. These payments were not made.
In February 2020, the note holder sued the Company and Mr. Diamantis, as guarantor, in New York State Court for the County of New York,
for approximately $2.2 million for non-payment of the promissory note. Mr. Diamantis was a former member of the Company Board of Directors.
In May 2020, the Company, Mr. Diamantis, as guarantor, and the note holder entered into a Stipulation providing for a payment of a total
of $2.2 million (which included accrued “penalty” interest as of that date) in installments through November 1, 2020. As
of March 31, 2021, $450,000 has been paid in cash and $2.0 million ($1.4 million of principal and $0.6 million of accrued “penalty”
interest), remains past due. The Stipulation is more fully discussed in Note 13.
On
January 29, 2020, the Company entered into the Installment Note in the principal amount of $1.2 million. Pursuant to the Installment
Note, weekly installment payments ranging from $22,500 to $34,000 were due on or before February 5, 2020 through on or before
October 21, 2020, the maturity date. The Installment Note, which was issued with an original issue discount in the amount of approximately
$0.1 million, is non-interest bearing and subject to a late-payment fee of 10%. The Company made payments totalling $1.1
million during the year ended December 31, 2020 and $20,000 during the three months ended March 31, 2021. As of March 31, 2021,
$0.1 million is past due, including a $9,850 late payment penalty.
As
of April 20, 2020 and through May 1, 2020, the Company and its subsidiaries received PPP loan proceeds in the form of promissory notes
(the “PPP Notes”) in the aggregate amount of approximately $2.4 million. The PPP Notes and accrued interest are forgivable
as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains
its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries. No collateral
or guarantees were provided in connection with the PPP Notes. The unforgiven portion of the PPP Notes are payable over two years at an
interest rate of 1.0% per annum, with a deferral of payments for the first sixteen months. Beginning sixteen months from the dates of
issuance, the Company is required (if not forgiven) to make monthly payments of principal and interest to the lenders. The aggregate
monthly payment of all of the PPP Notes is approximately $0.1 million. The Company believes that it has used the proceeds for purposes
consistent with the PPP. While the Company currently believes that its use of the loan proceeds has met the conditions for forgiveness
of the loans, it cannot assure you that it has not taken actions that could cause the Company to be ineligible for forgiveness of the
loans, in whole or in part. The Company is in the process of applying for forgiveness of the PPP Notes.
On
February 25, 2021, the Company entered into agreements with certain institutional investors for warrant prepayment promissory notes with
an aggregate principal amount of $550,000. The Company received proceeds of $500,000 from the payees who may at their option apply all
or any portion of the principal amount outstanding to the exercise of any warrants of the Company held by the payee. The notes are unsecured
and they mature 12 months from the date of issuance. The notes do not bear interest but an interest rate of 18% will be applied to the
outstanding principal commencing five days after any event of default that results in their acceleration.
Note
Payable – With Former Member of our Board of Directors
|
|
March 31, 2021
|
|
|
December 31, 2020
|
|
|
|
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
Loan payable to Christopher Diamantis
|
|
$
|
2,627,000
|
|
|
$
|
2,097,000
|
|
|
|
|
|
|
|
|
|
|
Total note payable, related party
|
|
|
2,627,000
|
|
|
|
2,097,000
|
|
|
|
|
|
|
|
|
|
|
Less current portion of notes payable, related party
|
|
|
(2,627,000
|
)
|
|
|
(2,097,000
|
)
|
Total note payable, related party, net of current portion
|
|
$
|
-
|
|
|
$
|
-
|
|
During
the three months ended March 31, 2021, Mr. Diamantis loaned the Company $0.5 million for working capital purposes. During the three months
ended March 31, 2020, Mr. Diamantis provided the Company $3.1 million for short-term working capital loans and, on behalf of the Company,
the payment of expenses and fees and a portion of the principal due on outstanding debentures. The $3.1 million provided also included
$0.4 million for interest incurred by Mr. Diamantis on borrowings he procured in order to loan funds to the Company.
During
the three months ended March 31, 2021 and 2020, the Company accrued interest of $53,000 and $0.3 million, respectively, on the
loans from Mr. Diamantis and it repaid $0 and $25,000, respectively, of loans from Mr. Diamantis. As of March 31, 2021 and December
31, 2020, accrued interest on the loans from Mr. Diamantis totalled $0.3 million and $0.2 million, respectively. Interest
accrues on loans from Mr. Diamantis at a rate of 10% on the majority of the amounts loaned. In addition, the Company incurs interest
expense related to the amounts Mr. Diamantis borrows from third-parties to loan to the Company.
Note
7 – Debentures
The
carrying amount of all outstanding debentures as of March 31, 2021 (unaudited), and December 31, 2020 is as follows:
|
|
March 31, 2021
|
|
|
December 31, 2020
|
|
|
|
|
|
|
|
|
Debentures
|
|
$
|
12,690,539
|
|
|
$
|
12,690,539
|
|
Less current portion
|
|
|
(12,690,539
|
)
|
|
|
(12,690,539
|
)
|
Debentures, net of current portion
|
|
$
|
-
|
|
|
$
|
-
|
|
Payment
of all outstanding debentures totalling $12.7 million, including late-payment penalties, at December 31, 2020 was past
due by the debentures’ original terms. The terms of the outstanding debentures as of December 31, 2020 are more fully described
in Note 9 to the Company’s consolidated financial statements included in its Annual Report on Form 10-K for the year ended
December 31, 2020. Certain of these debentures were issued with warrants to purchase shares of the Company’s common stock.
Outstanding warrants are more fully discussed in Note 11.
During
the three months ended March 31, 2021 and 2020, the Company accrued interest expense on outstanding debentures of $0.6 million and $1.9
million, respectively.
See
Note 11 for summarized information related to warrants issued and the activity during the three months ended March 31, 2021.
See
Notes 3 and 11 for a discussion of the dilutive effect of the outstanding convertible debentures and warrants as of March 31, 2021 and
Note 16 for the dilutive effect of outstanding convertible debentures and warrants as of June 2, 2021.
Note
8 – Related Party Transactions
Alcimede
LLC (“Alcimede”) billed $0.1 million and $0.1 million for consulting fees for the three months ended March 31, 2021 and 2020,
respectively. Seamus Lagan, the Company’s President and Chief Executive Officer, is the sole manager of Alcimede (also see Note
11).
The
terms of the foregoing transaction, including those discussed in Note 6 and 11 are not necessarily indicative of those that would have
been agreed to with unrelated parties for similar transactions.
Note
9 – Finance and Operating Lease Obligations
We
adopted ASU No. 2016-02, Leases (Topic 842), which requires leases with durations greater than 12 months to be recognized on the
balance sheet, effective January 1, 2019, using the modified retrospective approach. We lease property and equipment under finance and
operating leases. For leases with terms greater than 12 months, we record the related right-of-use assets and right-of-use obligations
at the present value of lease payments over the term. We do not separate lease and non-lease components of contracts.
Generally,
we use our most recent agreed upon borrowing interest rate at lease commencement as our interest rate, as most of our operating leases
do not provide a readily determinable implicit interest rate.
The
following table presents our lease-related assets and liabilities at March 31, 2021 and December 31, 2020:
|
|
Balance Sheet Classification
|
|
|
March 31,
2021
|
|
|
December 31,
2020
|
|
|
|
|
|
|
|
|
|
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating leases
|
|
Right-of-use operating lease assets
|
|
|
$
|
958,745
|
|
|
$
|
1,000,272
|
|
Finance leases
|
|
Property and equipment, net
|
|
|
|
249,985
|
|
|
|
249,985
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total lease assets
|
|
|
|
|
|
$
|
1,208,730
|
|
|
$
|
1,250,257
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Current:
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating leases
|
|
Right-of-use operating lease obligations
|
|
|
$
|
195,454
|
|
|
$
|
172,952
|
|
Finance leases
|
|
Current liabilities
|
|
|
|
249,985
|
|
|
|
249,985
|
|
Noncurrent:
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating leases
|
|
Right-of-use operating lease obligations
|
|
|
|
763,291
|
|
|
|
827,320
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total lease liabilities
|
|
|
|
|
|
$
|
1,208,730
|
|
|
$
|
1,250,257
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average remaining term:
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating leases
|
|
|
|
|
|
|
3.96 years
|
|
|
|
4.17 years
|
|
Finance leases
|
|
|
|
|
|
|
0 years
|
|
|
|
0 years
|
|
Weighted-average discount rate:
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating leases
|
|
|
|
|
|
|
13.0
|
%
|
|
|
13.0
|
%
|
Finance leases
|
|
|
|
|
|
|
4.9
|
%
|
|
|
4.9
|
%
|
The
following table presents certain information related to lease expense for finance and operating leases for the three months ended March
31, 2021 and 2020:
|
|
Three Months Ended
March 31, 2021
|
|
|
Three Months Ended
March 31, 2020
|
|
Finance
lease expense:
|
|
|
|
|
|
|
|
|
Depreciation/amortization
of leased assets
|
|
$
|
-
|
|
|
$
|
15,810
|
|
Interest
on lease liabilities
|
|
|
-
|
|
|
|
46,509
|
|
Operating
leases:
|
|
|
|
|
|
|
|
|
Short-term
lease expense (1)
|
|
|
72,650
|
|
|
|
100,706
|
|
Total
lease expense
|
|
$
|
72,650
|
|
|
$
|
163,025
|
|
(1)
|
Expenses
are included in general and administrative expenses in the consolidated statements of operations.
|
Other
Information
The
following table presents supplemental cash flow information for the three months ended March 31, 2021 and 2020:
|
|
Three Months Ended
March 31, 2021
|
|
|
Three Months Ended
March 31, 2020
|
|
Cash paid for amounts included in the measurement of lease liabilities:
|
|
|
|
|
|
|
|
|
Operating cash flows for operating leases obligations
|
|
$
|
34,861
|
|
|
$
|
18,000
|
|
Operating cash flows for finance leases
|
|
$
|
-
|
|
|
$
|
9,455
|
|
Financing cash flows for finance lease payments
|
|
$
|
-
|
|
|
$
|
100,707
|
|
Aggregate
future minimum lease payments under right-of-use operating and finance leases are as follows:
|
|
Right-of-Use
Operating
Leases
|
|
|
Finance
Leases
|
|
April 1, 2021 to March 31, 2022
|
|
$
|
309,718
|
|
|
$
|
253,776
|
|
April 1, 2022 to March 31, 2023
|
|
|
341,718
|
|
|
|
-
|
|
April 1, 2023 to March 31, 2024
|
|
|
243,270
|
|
|
|
-
|
|
April 1, 2024 to March 31, 2025
|
|
|
221,088
|
|
|
|
-
|
|
April 1, 2025 to March 31, 2026
|
|
|
130,547
|
|
|
|
-
|
|
Thereafter
|
|
|
|
|
|
|
|
|
Total
|
|
|
1,246,341
|
|
|
|
253,776
|
|
|
|
|
|
|
|
|
|
|
Less interest
|
|
|
(287,595
|
)
|
|
|
(3,791
|
)
|
Present value of minimum lease payments
|
|
|
958,746
|
|
|
|
249,985
|
|
|
|
|
|
|
|
|
|
|
Less current portion of lease obligations
|
|
|
(195,454
|
)
|
|
|
(249,985
|
)
|
Lease obligations, net of current portion
|
|
$
|
763,292
|
|
|
$
|
-
|
|
As
of March 31, 2021, the Company was in default under its finance lease obligation, therefore, the aggregate future minimum lease payments
and accrued interest under this finance lease in the amount of $0.2 million are deemed to be immediately due.
Note
10 – Derivative Financial Instruments and Fair Value
The
estimated fair value of financial instruments was determined by the Company using available market information and valuation methodologies
considered to be appropriate. At March 31, 2021 and December 31, 2020, the carrying value of the Company’s accounts receivable,
accounts payable and accrued expenses approximated their fair values due to their short-term nature.
The
following table sets forth the financial assets and liabilities carried at fair value measured on a recurring basis as of March 31, 2021
and December 31, 2020:
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2020:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Embedded conversion option
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
455,336
|
|
|
$
|
455,336
|
|
Total
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
455,336
|
|
|
$
|
455,336
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of March 31, 2021:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Embedded conversion option
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
455,336
|
|
|
$
|
455,336
|
|
Total
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
455,336
|
|
|
$
|
455,336
|
|
The
Company utilized the following method to value its derivative liability as of March 31, 2021 and December 31, 2020 for an embedded conversion
option that was valued at $455,336. The Company determined the fair value by comparing the discounted conversion price per share (85%
of market price) multiplied by the number of shares issuable at the balance sheet date to the actual price per share of the Company’s
common stock multiplied by the number of shares issuable at that date with the difference in value recorded as a liability. There was
no change in the value of the embedded conversion option in the three months ended March 31, 2021 and 2020 as there was no change in
the conversion price terms during the periods.
During
the three months ended March 31, 2021, the conversions of preferred stock triggered a further reduction in the exercise prices of warrants
containing ratchet features that had not already ratcheted down to their floor. In accordance with U.S. GAAP, the incremental fair value
of the debentures and warrants as a result of the decreases in the conversion/exercise prices was measured using Black Scholes. The following
assumptions were utilized in the Black Scholes valuation models: risk free rates ranging from 0.06% to 0.10%, volatility ranging from
213.25% to 243.58% and lives ranging from .91 years to 1.21 years. The incremental fair value of $50.4 million was recorded as deemed
dividends for the three months ended March 31, 2021. No deemed dividends were recorded in the three months ended March 31, 2020 as no
down round provisions were triggered during the period. Deemed dividends are also discussed in Notes 1 and 3.
Note
11 – Stockholders’ Deficit
Authorized
Capital
The
Company has 10,000,000,000 authorized shares of Common Stock at $0.0001 par value and 5,000,000 authorized shares of Preferred Stock
at a par value of $0.01.
Preferred
Stock
The
Company has 5,000,000 shares, par value $0.01, of preferred stock authorized. As of March 31, 2021, the Company had outstanding shares
of preferred stock consisting of 10 shares of its Series H Convertible Preferred Stock (the “Series H Preferred Stock”),
1,750,000 shares of its Series F Convertible Preferred Stock (the “Series F Preferred Stock”), 250,000 shares of its Series
L Convertible Preferred Stock (the “Series L Preferred Stock”), 22,000 shares of its Series M Redeemable Convertible Preferred
Stock (the “Series M Preferred Stock”) and 25,257 shares of its Series N Convertible Redeemable Preferred Stock (the “Series
N Preferred Stock”).
The
Series H Preferred Stock has a stated value of $1,000 per share and is convertible into shares of the Company’s common stock at
a conversion price of 85% of the volume weighted average price of the Company’s common stock at the time of conversion.
In
September 2017, the Company issued 1,750,000 shares of its Series F Preferred Stock valued at $174,097 in connection with the acquisition
of Genomas Inc. Genomas Inc. is included in the Company’s discontinued operations as part of the AMSG & HTS Group. Discontinued
operations are discussed in Note 14. As a result of the Reverse Stock Split, the maximum number of shares of common stock issuable upon
the conversion of the Series F Preferred Stock is one. Any shares of Series F Preferred Stock outstanding on the fifth anniversary of
the issuance date will be mandatorily converted into common stock at the applicable conversion price on such date. The Series F Preferred
Stock has voting rights. Each share of Series F Preferred Stock has one vote, and the holders of the Series F Preferred Stock shall vote
together with the holders of the Company’s common stock as a single class.
On
May 4, 2020, the Company filed a Certificate of Designation with the Secretary of State of the State of Delaware to authorize the issuance
of up to 250,000 shares of its Series L Preferred Stock. On May 5, 2020, the Company entered into an exchange agreement with Alcimede.
Pursuant to the exchange agreement, the Company issued to Alcimede 250,000 shares of its Series L Preferred Stock in exchange for the
250,000 shares of the Company’s Series K Preferred Stock held by Alcimede. Upon the issuance of the Series L Preferred Stock to
Alcimede, the shares of Series K Preferred Stock were cancelled. The Series L Preferred Stock was not convertible into common stock prior
to December 1, 2020 and is not entitled to receive any dividends. Each share of the Series L Preferred Stock is convertible into shares
of the Company’s common stock at a conversion price equal to the average closing price of the Company’s common stock on the
ten trading days immediately prior to the conversion date.
Series
M Preferred Stock Exchanged for Loans from Mr. Diamantis
The
Company’s Board of Directors has designated 30,000 shares of the 5,000,000 shares of authorized preferred stock as the Series
M Preferred Stock. Each share of Series M Preferred Stock has a stated value of $1,000. On June 30, 2020, the Company and Mr.
Diamantis entered into an exchange agreement wherein Mr. Diamantis agreed to the extinguishment of the Company’s indebtedness
to Mr. Diamantis totalling $18.8 million, including accrued interest, on that date in exchange for 22,000 shares of the
Company’s Series M Preferred Stock with a par value of $0.01 per share. As a result of the exchange, the Company recorded
a deemed dividend of approximately $3.2 million in the year ended December 31, 2020, which represented the difference between
the $18.8 million of debt and accrued interest exchanged and the value of the Series M Preferred Stock of $22.0 million. See Note
6 for a discussion of the Company’s current indebtedness to Mr. Diamantis.
The
terms of the Series M Preferred Stock were set forth in the Company’s Current Report on Form 8-K filed with the SEC on June 16,
2020. In particular: (i) each holder of the Series M Preferred Stock shall be entitled to vote on all matters submitted to a vote of
the holders of the Company’s common stock. Regardless of the number of shares of Series M Preferred Stock outstanding and so long
as at least one share of Series M Preferred Stock is outstanding, the outstanding shares of Series M Preferred Stock shall have the number
of votes, in the aggregate, equal to 51% of all votes entitled to be voted at any meeting of stockholders or action by written consent.
Each outstanding share of the Series M Preferred Stock shall represent its proportionate share of the 51% allocated to the outstanding
shares of Series M Preferred Stock in the aggregate. The Series M Preferred Stock shall vote with the common stock and any other voting
securities as if they were a single class of securities; (ii) each share of the Series M Preferred Stock is convertible into shares of
the Company’s common stock at a conversion price equal to 90% of the average closing price of the Company’s common stock
on the ten trading days immediately prior to the conversion date but in any event not less than the par value of the Company’s
common stock; and (iii) dividends at the rate per annum of ten percent (10%) of the stated value per share shall accrue on each outstanding
share of Series M Preferred Stock from and after the date of the original issuance of such share of Series M Preferred Stock (subject
to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization). The dividends
shall accrue from day to day, whether or not declared, and shall be cumulative and non-compounding; provided, however,
that such dividend shall be payable only when, as, and if declared by the Board of Directors and the Company shall be under no obligation
to pay such dividends. No cash dividends shall be paid on the Company’s common stock unless the dividends are paid on the Series
M Preferred Stock.
On
August 13, 2020, Mr. Diamantis entered into a Voting Agreement and Irrevocable Proxy with the Company, Mr. Lagan and Alcimede (of which
Mr. Lagan is the sole manager) pursuant to which Mr. Diamantis granted an irrevocable proxy to Mr. Lagan to vote the Series M Preferred
Stock held by Mr. Diamantis, Mr. Diamantis has retained all other rights under the Series M Preferred Stock.
Series
N Preferred Stock Exchanged for Series I-1 and Series I-2 Preferred Stock and Debentures
On
August 31, 2020, the Company filed a certificate of designation to authorize 50,000 shares of its newly-authorized Series N Preferred
Stock with a stated value of $1,000 per share. On August 31, 2020, the Company and its debenture holders exchanged, under the terms of
the Exchange and Redemption Agreement, certain outstanding debentures and all of the outstanding shares of the Company’s Series
I-1 Convertible Preferred Stock (the “Series I-1 Preferred Stock”) and Series I-2 Convertible Preferred Stock (the “Series
I-2 Preferred Stock”) for 30,435.52 shares of the Company’s Series N Preferred Stock.
The
terms of the Series N Preferred Stock were set forth in the Company’s Current Report on Form 8-K filed with the SEC on September
1, 2020, In particular:
Voting
Rights. Except as provided below or by law, the Series N Preferred Stock shall have no voting rights. However, as long as any shares
of Series N Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the
then outstanding shares of the Series N Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the
Series N Preferred Stock or alter or amend the Certificate of Designation, (b) amend its certificate of incorporation or other charter
documents in any manner that adversely affects any rights of the holders, (c) increase the number of authorized shares of the Series
N Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing.
Dividends.
Dividends at the rate per annum of 10% of the stated value per share shall accrue on each outstanding share of Series N Preferred Stock
from and after the date of the original issuance of such share of Series N Preferred Stock (the “Preferred Accruing Dividends”).
The Preferred Accruing Dividends shall accrue from day to day, whether or not declared, and shall be cumulative and non-compounding;
provided, however, that such Preferred Accruing Dividends shall be payable only when, as, and if declared by the Board
of Directors. No cash dividends shall be paid on the common stock unless the Preferred Accruing Dividends are paid.
Rank.
The Series N Preferred Stock ranks with respect to dividends or a liquidation, (i) on parity with the common stock, the Company’s
Series H Preferred Stock, the Company’s Series L Preferred Stock and the Company’s Series M Preferred Stock, (ii) senior
to the Company’s Series F Preferred Stock, and (iii) junior to any other class or series of preferred stock of the Company afterwards
created and ranking by its terms senior to the Series N Preferred Stock.
Conversion.
Each share of the Series N Preferred Stock is convertible into shares of the Company’s common stock, at any time and from time
to time, at the option of the holder, into that number of shares of common stock determined by dividing the stated value of such share
of Series N Preferred Stock, plus any accrued declared and unpaid dividends, by the conversion price. The conversion price is equal to
90% of the lowest VWAP during the 10 trading days immediately prior to the conversion date. Holders of the Series N Preferred Stock are
prohibited from converting Series N Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together
with its affiliates, would own more than 4.99% (or, upon election of the holder, 9.99%) of the total number of shares of common stock
then issued and outstanding. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%,
provided that any increase in such percentage shall not be effective until 61 days after notice to the Company.
Liquidation
Preference. Upon any liquidation, dissolution or winding up of the Company, the holders of the Series N Preferred Stock shall be
entitled to receive an amount equal to the stated value of the Series N Preferred Stock, plus any accrued declared and unpaid dividends
thereon and any other fees or liquidated damages then due and owing thereon, for each share of the Series N Preferred Stock before any
distribution or payment shall be made on any junior securities.
Redemption.
At any time the Company shall have the right to redeem all, or any part, of the Series N Preferred Stock then outstanding. The Series
N Preferred Stock subject to redemption shall be redeemed by the Company in cash in an amount equal to the stated value of the shares
of the Series N Preferred Stock being redeemed plus all accrued declared and unpaid dividends.
During
the year ended December 31, 2020, the holders converted 1,001 shares of their Series N Preferred Stock, with a stated value of $1,001,000,
into 38,371,250 shares of the Company’s common stock. During the three months ended March 31, 2021, the holders converted 4,177.516
shares of their Series N Preferred Stock, with a stated value of $4,177,516, into 435,082,000 shares of the Company’s common stock.
Common
Stock
The
Company had 474,730,679 and 39,648,679 shares of its common stock issued and outstanding at March 31, 2021 and December 31, 2020, respectively.
During the three months ended March 31, 2021, the Company issued 435,082,000 shares of its common stock upon the conversions of 4,177.516
shares of its Series N Preferred Stock. During the three months ended March 31, 2020, the Company issued 25,000 shares of its common
stock upon the conversions of 21.25 shares of its Series I-2 Preferred Stock.
Common
Stock and Common Stock Equivalents
The
Company has outstanding options, warrants, convertible preferred stock and convertible debentures. Exercise of the options and warrants,
and conversions of the convertible preferred stock and debentures could result in substantial dilution of the Company’s common
stock and a decline in the market price of the common stock. In addition, the terms of certain of the warrants, convertible preferred
stock and convertible debentures issued by the Company provide for reductions in the per share exercise prices of the warrants and the
per share conversion prices of the debentures and preferred stock (if applicable and subject to a floor in certain cases), in the event
that the Company issues common stock or common stock equivalents (as that term is defined in the agreements) at an effective exercise/conversion
price that is less than the then exercise/conversion prices of the outstanding warrants, preferred stock or debentures, as the case may
be. These provisions, as well as the issuances of debentures and preferred stock with conversion prices that vary based upon the price
of our common stock on the date of conversion, have resulted in significant dilution of the Company’s common stock and have given
rise to reverse splits of its common stock. See Note 16 for a discussion of the number of shares of the Company’s common stock
and common stock equivalents outstanding as of June 2, 2021.
On
August 13, 2020, Mr. Diamantis entered into the Voting Agreement with the Company, Mr. Lagan and Alcimede (of which Mr. Lagan is the
sole manager) pursuant to which Mr. Diamantis granted an irrevocable proxy to Mr. Lagan to vote the Series M Preferred Stock held by
Mr. Diamantis, Mr. Diamantis has retained all other rights under the Series M Preferred Stock. Regardless of the number of shares of
Series M Preferred Stock outstanding and so long as at least one share of Series M Preferred Stock is outstanding, the outstanding shares
of Series M Preferred Stock shall have the number of votes, in the aggregate, equal to 51% of all votes entitled to be voted at any meeting
of stockholders or action by written consent. This means that the holders of Series M Preferred Stock have sufficient votes, by themselves,
to approve or defeat any proposal voted on by the Company’s stockholders, unless there is a supermajority required under applicable
law or by agreement. As a result of the Voting Agreement, as of the date of filing this report, the Company believes that it has the
ability to ensure that it has and or can obtain sufficient authorized shares of its common stock to cover all potentially dilutive common
shares outstanding.
Stock
Options
The
Company maintained and sponsored the Tegal Corporation 2007 Incentive Award Equity Plan (the “2007 Equity Plan”). Tegal Corporation
is the prior name of the Company. The 2007 Equity Plan, as amended, provided for the issuance of stock options and other equity awards
to the Company’s officers, directors, employees and consultants. The 2007 Equity Plan terminated pursuant to its terms in September
2017. The following table summarizes the stock option activity for the three months ended March 31, 2021:
|
|
Number of
Options
|
|
|
Weighted-
average
exercise price
|
|
|
Weighted-
average
contractual term
|
|
Outstanding at December 31, 2020
|
|
|
26
|
|
|
$
|
2,992,125
|
|
|
|
5.37
|
|
Granted
|
|
|
-
|
|
|
|
|
|
|
|
|
|
Expired
|
|
|
-
|
|
|
|
|
|
|
|
|
|
Outstanding at March 31, 2021
|
|
|
26
|
|
|
$
|
2,992,125
|
|
|
|
5.15
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable at March 31, 2021
|
|
|
26
|
|
|
$
|
2,992,125
|
|
|
|
|
|
As
of March 31, 2021, the weighted average remaining contractual life was 5.15 years for options outstanding and exercisable. The intrinsic
value of options exercisable at March 31, 2021 and December 31, 2010 was $0. As of March 31, 2021 and December 31, 2020, there was no
remaining compensation expense as all of the outstanding options had fully vested as of December 31, 2019. When valuing stock options,
the Company’s policy is to estimate forfeiture and volatility using historical information. The risk-free interest rate used is
based on the implied yield available on U.S. Treasury zero-coupon issues over the equivalent lives of the options. The expected life
of the options represents the estimated period using the simplified method. The Company has not paid cash dividends on its common stock
and no assumption of dividend payment(s) is made in the valuation model.
Warrants
The
Company, as part of various debt and equity financing transactions, has issued warrants to purchase shares of the Company’s
common stock totalling 13.8 billion at March 31, 2021. During the three months ended March 31, 2021 and the year ended
December 31, 2020, as a result of the anti-dilution provisions of outstanding warrants, the exercise prices of certain warrants
decreased and they became exercisable into an additional 9.3 billion and 4.5 billion shares of the Company’s common stock,
respectively. Certain of these warrants were issued in connection with the issuances of the debentures. Debentures are more fully
discussed in Note 7.
Warrants
Issued with March 2017 Debentures
The
Company has outstanding warrants that were issued in various equity financings as noted above. Included in the warrants outstanding
at March 31, 2021, were warrants issued in connection with the debentures issued in March 2017. The Company issued these warrants to purchase shares of the Company’s common stock to several accredited investors (the “March Warrants”).
At March 31, 2021, these warrants were exercisable into an aggregate of approximately 12.3 billion shares of the Company’s
common stock. The March Warrants were issued to the investors in three tranches, Series A Warrants, Series B Warrants and Series
C Warrants. At March 31, 2021, the Series A Warrants were exercisable for 4.6 billion shares of the Company’s common stock.
They were exercisable upon issuance and have a term of exercise equal to five years. At March 31, 2021, the Series B Warrants
were exercisable for 2.9 billion shares of the Company’s common stock and are exercisable until March 31, 2022. At March
31, 2021, the Series C Warrants were exercisable for 4.8 billion shares of the Company’s common stock and have a term of
five years provided such warrants shall only vest if, when and to the extent that the holders exercise the Series B Warrants.
At March 31, 2021, the Series A, Series B and Series C Warrants each have an exercise price of $0.0039 per share, which reflects
adjustments pursuant to their terms. The March Warrants are subject to “full ratchet” and other customary anti-dilution
protections. During the three months ended March 31, 2021, reductions in the exercise prices of the March Warrants have given
rise to deemed dividends as more fully discussed in Notes 1, 3 and 10.
In
connection with debentures issued in September 2017, the Company issued warrants to purchase shares of the Company’s common stock.
At March 31, 2021, these warrants were exercisable into approximately six shares of common stock and they expire on varying dates in
2022. At March 31, 2021, the exercise price of these warrants was $9,016,133 per share, which is the per share floor exercise price as
a result of reverse stock splits of the Company’s common stock that have been effected since these warrants were issued.
The
number of warrants issued, converted and outstanding as well as the exercise prices of the warrants reflected in the table below have
been adjusted to reflect the full ratchet and other dilutive and down round provisions pursuant to the warrant agreements. As a result
of the full ratchet provisions of the majority of the outstanding warrants (subject to a floor in some cases), subsequent issuances of
the Company’s common stock or common stock equivalents at prices below the then current exercise prices of the warrants have resulted
in increases in the number of shares issuable pursuant to the warrants and decreases in the exercise prices of the warrants.
The
following summarizes the information related to warrant activity during the three months ended March 31, 2021:
|
|
Number of
Warrants
|
|
|
Weighted
average
exercise price
|
|
Balance at December 31, 2020
|
|
|
4,571,165,207
|
|
|
$
|
0.0200
|
|
Increase in warrants during the period as a result of down round
provisions
|
|
|
9,259,539,746
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at March 31, 2021
|
|
|
13,830,704,953
|
|
|
$
|
0.0066
|
|
See
above and Notes 1, 3, 10, 11 and 16 for a discussion of the dilutive effect of the outstanding warrants.
Note
12 – Supplemental Disclosure of Cash Flow Information
|
|
Three Months Ended March 31,
|
|
|
|
2021
|
|
|
2020
|
|
Cash paid for interest
|
|
$
|
-
|
|
|
$
|
-
|
|
Cash paid for income taxes
|
|
$
|
281,025
|
|
|
$
|
-
|
|
|
|
|
|
|
|
|
|
|
Non-cash investing and financing activities:
|
|
|
|
|
|
|
|
|
Series I-2 Preferred Stock converted into common stock
|
|
$
|
-
|
|
|
$
|
25,000
|
|
Series N Preferred Stock converted into common stock
|
|
$
|
4,177,156
|
|
|
$
|
-
|
|
Deemed dividends for trigger of down round provisions
|
|
$
|
50,358,149
|
|
|
$
|
-
|
|
Note
13 – Commitments and Contingencies
Concentration
of Credit Risk
Credit
risk with respect to accounts receivable is generally diversified due to the large number of patients comprising the accounts receivable.
The Company has receivable balances with government payers and various insurance carriers. The Company does not require collateral or
other security to support customer receivables. However, the Company continually monitors and evaluates its collection procedures to
minimize potential credit risks associated with its accounts receivable and establishes an allowance for uncollectible accounts and as
a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is not material to the financial statements.
A
number of proposals for legislation continue to be under discussion which could substantially reduce Medicare and Medicaid (CMS) reimbursements
to hospitals and clinical laboratories. Depending upon the nature of regulatory action, and the content of legislation, the Company could
experience a significant decrease in revenues from Medicare and Medicaid (CMS), which could have a material adverse effect on the Company.
The Company is unable to predict, however, the extent to which such actions will be taken.
The
Company maintains its cash balances in high credit quality financial institutions. The Company’s cash balances may, at times, exceed
the deposit insurance limits provided by the Federal Deposit Insurance Corp.
Legal
Matters
From
time to time, the Company may be involved in a variety of claims, lawsuits, investigations and proceedings related to contractual disputes,
employment matters, regulatory and compliance matters, intellectual property rights and other litigation arising in the ordinary course
of business. The Company operates in a highly regulated industry which may inherently lend itself to legal matters. Management is aware
that litigation has associated costs and that results of adverse litigation verdicts could have a material effect on the Company’s
financial position or results of operations. The Company’s policy is to expense legal fees and expenses incurred in connection
with the legal proceedings in the period in which the expense is incurred. Management, in consultation with legal counsel, has addressed
known assertions and predicted unasserted claims below.
Biohealth
Medical Laboratory, Inc. and PB Laboratories, LLC (the “Companies”) filed suit against CIGNA Health in 2015 alleging that
CIGNA failed to pay claims for laboratory services the Companies provided to patients pursuant to CIGNA - issued and CIGNA - administered
plans. In 2016, the U.S. District Court dismissed part of the Companies’ claims for lack of standing. The Companies appealed that
decision to the Eleventh Circuit Court of Appeals, which in late 2017 reversed the District Court’s decision and found that the
Companies have standing to raise claims arising out of traditional insurance plans as well as self-funded plans. In July 2019, the Companies
and EPIC Reference Labs, Inc. filed suit against CIGNA Health for failure to pay claims for laboratory services provided. Cigna Health,
in turn, sued for improper billing practices. CIGNA’s case against the Company was dismissed on June 22, 2020. The suit remains
ongoing but because the Company did not have the financial resources to see the legal action to conclusion it assigned the benefit, if
any, from the suit to Christopher Diamantis for his assumption of the costs to carry the cost to conclusion.
In
November of 2016, the IRS commenced an audit of the Company’s 2015 Federal tax return. Based upon the audit results, the Company
made provisions of approximately $1.0 million as a liability and approximately $0.9 million as a receivable in its financial statements
for the year ended December 31, 2018. During the first quarter of 2020, the U.S. Congress approved the CARES Act, which allows a five-year
carryback privilege for federal net operating tax losses that arose in a tax year beginning in 2018 and through 2020. As a result, during
the three months ended March 31, 2020, the Company recorded approximately $1.1 million in refunds from the carryback of certain of its
federal net operating losses. During the three months ended March 31, 2021, the Company received income tax refunds of $0.3 million,
which represented income tax refunds associated with the CARES Act. No refunds were received during the three months ended March 31,
2020. The Company used the $0.3 million of refunds that it received in the three months ended March 31, 2021 to repay a portion of the
amount that it owes for federal income tax liabilities that arose from the 2015 federal income tax audit. As of March 31, 2021, the Company
had federal income tax receivables of $1.1 million and federal income tax liabilities of $0.8 million.
On
September 27, 2016, a tax warrant was issued against the Company by the Florida Department of Revenue (the “DOR”) for unpaid
2014 state income taxes in the approximate amount of $0.9 million, including penalties and interest. The Company entered into a Stipulation
Agreement with the DOR allowing the Company to make monthly installments until July 2019. The Company has made payments to reduce the
amount owed. The Company intends to renegotiate another Stipulation agreement. However, there can be no assurance the Company will be
successful. The balance accrued of approximately $0.4 million remained outstanding to the DOR at March 31, 2021.
In
December of 2016, DeLage Landen Financial Services, Inc. (“DeLage”), filed suit against the Company for failure to make the
required payments under an equipment leasing contract that the Company had with DeLage (see Note 9). On January 24, 2017, DeLage received
a default judgment against the Company in the approximate amount of $1.0 million, representing the balance owed on the lease, as well
as additional interest, penalties and fees. The Company recognized this amount in its consolidated financial statements as of December
31, 2016. On February 8, 2017, a Stay of Execution was filed and under its terms the balance due was to be paid in variable monthly installments
through January of 2019, with an implicit interest rate of 4.97%. The Company and DeLage disposed of certain equipment and reduced the
balance owed to DeLage. A balance of $0.2 million remained outstanding at March 31, 2021.
On
December 7, 2016, the holders of the Tegal Notes (see Note 6) filed suit against the Company seeking payment for the amounts due under
the notes in the aggregate of the principal of $341,612, and accrued interest of $43,000. A request for entry of default judgment was
filed on January 24, 2017. On April 23, 2018, the holders of the Tegal Notes received a judgment against the Company. As of March 31,
2021, the Company has repaid $48,820 of the principal amount of these notes.
The
Company, as well as many of its subsidiaries, are defendants in a case filed in Broward County Circuit Court by TCA Global Credit Master
Fund, L.P. The plaintiff alleges a breach by Medytox Solutions, Inc. of its obligations under a debenture and claims damages of approximately
$2,030,000 plus interest, costs and fees. The Company and the other subsidiaries are sued as alleged guarantors of the debenture. The
complaint was filed on August 1, 2018. The Company has recorded the principal balance and interest owed under the debenture agreement
for the period ended March 31, 2021 (see Note 6). The Company and all defendants have filed a motion to dismiss the complaint, but have
not recorded any potential liability related to any further damages. In May 2020, the SEC appointed a Receiver to close down the TCA
Global Master Fund, L.P. over allegations of accounting fraud. The amount recorded by the Company as being owed to TCA was based on TCA’s
application of prior payments made by the Company. The Company believes that prior payments of principal and interest may have been applied
to unenforceable investment banking and other fees and charges. It is the Company’s position that the amount owed to TCA is less
than what is set forth in Note 6 and the Company intends to negotiate a settlement with the Receiver.
On
September 13, 2018, Laboratory Corporation of America sued EPIC Reference Labs, Inc., a subsidiary of the Company, in Palm Beach County
Circuit Court for amounts claimed to be owed. The court awarded a judgment against EPIC Reference Labs, Inc. in May 2019 for approximately
$155,000. The Company has recorded the amount owed as a liability as of March 31, 2021.
In
February 2020, Anthony O. Killough sued the Company and Mr. Diamantis, as guarantor, in New York State Court for the County of New York,
for approximately $2.0 million relating to the promissory note issued by the Company in September 2019. In May 2020, the parties entered
into a Stipulation providing for a payment of a total of $2,158,168 (which includes accrued interest) in installments through November
1, 2020 (See Note 6). As of March 31, 2021, the Company has not made the majority of the required payments and, as a result, approximately
$2.0 million, which includes penalty interest at a rate of 20% per annum, is due and owing.
In
February 2021, a supplier to the Company’s hospitals, Shared Medical Services, Inc., filed suit in Palm Beach County Circuit
Court for approximately $90,000 by virtue of default and for breach of contract and charges totalling approximately another
$100,000. The Company disputes that it has any liability or responsibility under the agreements and has filed an initial response
in the matter.
Following
the Company’s decision to suspend operations at Jamestown Regional Medical Center in June 2019 a number of vendors remain unpaid.
A number have initiated or threatened legal actions. The Company believes it will come to satisfactory arrangements with these parties
as it works toward reopening the hospital. The Company has accrued the amounts that it expects to owe in its financial statements. The
Company is planning to reopen the hospital upon securing adequate capital to do so. The reopening plans and timing thereof have also
been disrupted by the current pandemic.
Two
former employees of Jamestown Regional Medical Center have filed suit alleging violations of the federal Worker Adjustment and Retraining
Notification Act (“WARN”). The Court entered a default against the Company on August 14, 2019. The parties disagreed to the
amount of damages, specifically to whether part-time employees are entitled to WARN act damages. The parties have agreed and are in support
of a confidential settlement agreement, which is in the final stage of agreement, is expected to be concluded in the second quarter of
2021. The Company has accrued the estimated settlement amount.
In
June 2019, CHSPSC, the former owners of Jamestown Regional Medical Center obtained a judgment against the Company in the amount of $592,650.
The Company has recorded $130,000 of this judgment as a liability as of March 31, 2021, as management believes that a number of insurance
payments were made to CHSPCS after the change of ownership and will likely offset the majority of the claim made by CHSPCS.
In
August 2019, Morrison Management Specialists, Inc. obtained a judgment against Jamestown Regional Medical Center and the Company in Fentress
County, Tennessee in the amount of $194,455 in connection with housekeeping and dietary services. The Company has recorded this liability
as of March 31, 2021.
In
November 2019, Newstat, PLLC obtained a judgment against Big South Fork Medical Center in Knox County, Tennessee in the amount of $190,600
in connection with the provision of medical services. The Company has recorded this liability as of March 31, 2021.
Note
14 – Discontinued Operations
On
July 12, 2017, the Company announced plans to spin off AMSG and in the third quarter 2017 our Board of Directors voted unanimously to
spin off the Company’s wholly-owned subsidiary, HTS, as independent publicly traded companies by way of tax-free distributions
to the Company’s stockholders.
On
June 10, 2020, the Company signed an agreement for the separation of these entities into a public company. The agreement with TPT Global
Tech, Inc. (“TPT”) (OTC: TPTW), a California-based public company, was to merge HTS and AMSG into a public company after
TPT completed a merger of its wholly-owned subsidiary, InnovaQor, Inc., with this public company. Rennova terminated its agreement with
TPT on March 8, 2021 after numerous attempts to close the transaction as proposed failed due to uncertainty and last minute unviable
demands from TPT that would have created a high risk to the future success of the project. On March 23, 2021, TPT changed the name of
InnovaQor, Inc. to TPT Strategic, Inc. Rennova is currently considering the actions of TPT with the belief that TPT acted outside of
agreements that were in place and may have converted Rennova owned confidential information for its own benefit. Rennova intends to pursue
any remedy available to it under the law to recover money owed from TPT and to protect its technology and assets.
On
May 13, 2021, Rennova signed an agreement with VisualMED Clinical Solutions Corp. (“VisualMED”) a Nevada based public
company, for VisualMED to acquire AMSG & HTS. After closing these entities will operate as wholly owned subsidiaries of VisualMED.
Closing is subject to a number of customary conditions for a transaction of this nature and was intended to happen on or before
May 31, 2021. As part of the agreement, VisualMED is required to complete any outstanding applications necessary to be
fully compliant with OTC requirements before closing. VisualMED is in process of completing these applications but delayed communication
from the OTC Markets has resulted in the May 31, 2021 timeframe not being met. The Company anticipates this agreement to close
successfully in the coming weeks. Once the agreement has closed, VisualMED intends to file audited financial statements and other
filings as required to become fully reporting with the SEC.
In
accordance with ASC 205-20 and having met the criteria for “held for sale”, the Company has reflected amounts relating to
AMSG and HTS (referred to below as the AMSG & HTS Group) as a disposal group classified as held for sale and included as part of
discontinued operations.
EPIC
Reference Labs, Inc.
During
the three months ended September 30, 2020, the Company announced that it had reached a tentative agreement to sell its last clinical
laboratory, EPIC Reference Labs, Inc., to TPT and it made a decision to discontinue several other non-operating subsidiaries, and as
a result, EPIC Reference Labs, Inc.’s operations and the other non-operating subsidiaries have been classified as held for sale
and included in discontinued operations for all periods presented.
On
March 10, 2021, Rennova terminated the proposed agreement that it had entered into with TPT on August 6, 2020 for the purchase and sale
of EPIC Reference Labs, Inc. The Company also terminated an Interim Management Agreement with TPT entered into on August 6, 2020 granting
TPT an exclusive right and responsibility to undertake certain management and financial responsibility of EPIC Reference Labs, Inc.,
on our behalf and terminated all rights and approvals granted under letters dated November 2, 2020 and November 24, 2020 in reference
to the Quicklab Application in partnership with EPIC Reference Labs, Inc. Rennova intends to pursue whatever legal action necessary against
TPT and TPT Medtech, LLC to recover money and damages owed from the breach of these agreements by TPT and to stop TPT from all activities
that utilize or have been derived from their access to and use of Rennova owned confidential information.
Carrying
amounts of major classes of assets and liabilities classified as held for sale and included as part of discontinued operations in the
consolidated balance sheets as of March 31, 2021 and December 31, 2020 consisted of the following:
AMSG
& HTS Group Assets and Liabilities:
|
|
March 31, 2021
|
|
|
December 31, 2020
|
|
|
|
(unaudited)
|
|
|
|
|
Cash
|
|
$
|
6,887
|
|
|
$
|
31,294
|
|
Accounts receivable, net
|
|
|
138,466
|
|
|
|
151,363
|
|
Prepaid expenses and other current assets
|
|
|
858
|
|
|
|
1,717
|
|
Current assets classified as held for sale
|
|
$
|
146,211
|
|
|
$
|
184,374
|
|
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
$
|
948
|
|
|
$
|
685
|
|
Deposits
|
|
|
-
|
|
|
|
-
|
|
Right of use assets
|
|
|
-
|
|
|
|
-
|
|
Non-current assets classified as held for sale
|
|
$
|
948
|
|
|
$
|
685
|
|
|
|
|
|
|
|
|
|
|
Accounts payable and checks issued in excess of bank balance
|
|
$
|
711,305
|
|
|
$
|
726,220
|
|
Accrued expenses
|
|
|
1,311,146
|
|
|
|
1,308,283
|
|
Current portion of right-of-use operating lease obligation
|
|
|
-
|
|
|
|
-
|
|
Current portion of notes payable
|
|
|
216,269
|
|
|
|
168,751
|
|
Current liabilities classified as held for sale
|
|
$
|
2,238,720
|
|
|
$
|
2,203,254
|
|
|
|
|
|
|
|
|
|
|
Note payable
|
|
$
|
82,151
|
|
|
$
|
69,267
|
|
Right-of-use operating lease obligation
|
|
|
-
|
|
|
|
-
|
|
Non-current liabilities classified as held for sale
|
|
$
|
82,151
|
|
|
$
|
69,267
|
|
EPIC
Reference Labs, Inc. and Other Subsidiaries Assets and Liabilities
|
|
March 31, 2021
|
|
|
December 31, 2020
|
|
|
|
(unaudited)
|
|
|
|
|
Cash
|
|
$
|
1,596
|
|
|
$
|
136
|
|
Accounts receivable, net
|
|
|
-
|
|
|
|
-
|
|
Prepaid expenses and other current assets
|
|
|
-
|
|
|
|
-
|
|
Current assets classified as held for sale
|
|
$
|
1,596
|
|
|
$
|
136
|
|
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
$
|
-
|
|
|
$
|
-
|
|
Deposits
|
|
|
100,014
|
|
|
|
100,014
|
|
Right-of-use assets
|
|
|
76,587
|
|
|
|
100,116
|
|
Non-current assets classified as held for sale
|
|
$
|
176,601
|
|
|
$
|
200,130
|
|
|
|
|
|
|
|
|
|
|
Accounts payable and checks in excess of bank balance
|
|
$
|
1,193,766
|
|
|
$
|
1,185,158
|
|
Accrued expenses
|
|
|
334,882
|
|
|
|
334,667
|
|
Current portion of right-of-use operating lease obligation
|
|
|
76,587
|
|
|
|
91,166
|
|
Current portion of notes payable
|
|
|
-
|
|
|
|
-
|
|
Current liabilities classified as held for sale
|
|
$
|
1,605,235
|
|
|
$
|
1,610,991
|
|
|
|
|
|
|
|
|
|
|
Note payable
|
|
$
|
-
|
|
|
$
|
-
|
|
Right-of-use operating lease obligation
|
|
|
-
|
|
|
|
8,950
|
|
Non-current liabilities classified as held for sale
|
|
$
|
-
|
|
|
$
|
8,950
|
|
Consolidated
Discontinued Operations Assets and Liabilities:
|
|
March 31, 2021
|
|
|
December 31, 2020
|
|
|
|
(unaudited)
|
|
|
|
|
Cash
|
|
$
|
8,483
|
|
|
$
|
31,430
|
|
Accounts receivable, net
|
|
|
138,466
|
|
|
|
151,363
|
|
Prepaid expenses and other current assets
|
|
|
858
|
|
|
|
1,717
|
|
Current assets classified as held for sale
|
|
$
|
147,807
|
|
|
$
|
184,510
|
|
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
$
|
948
|
|
|
$
|
685
|
|
Deposits
|
|
|
100,014
|
|
|
|
100,014
|
|
Right-of-use assets
|
|
|
76,587
|
|
|
|
100,116
|
|
Non-current assets classified as held for sale
|
|
$
|
177,549
|
|
|
$
|
200,815
|
|
|
|
|
|
|
|
|
|
|
Accounts payable and checks issued in excess of bank balance
|
|
$
|
1,905,071
|
|
|
$
|
1,911,378
|
|
Accrued expenses
|
|
|
1,646,028
|
|
|
|
1,642,950
|
|
Current portion of right-of-use operating lease obligation
|
|
|
76,587
|
|
|
|
91,166
|
|
Current portion of notes payable
|
|
|
216,269
|
|
|
|
168,751
|
|
Current liabilities classified as held for sale
|
|
$
|
3,843,955
|
|
|
$
|
3,814,245
|
|
|
|
|
|
|
|
|
|
|
Note payable
|
|
$
|
82,151
|
|
|
$
|
69,267
|
|
Right-of-use operating lease obligation
|
|
|
-
|
|
|
|
8,950
|
|
Non-current liabilities classified as held for sale
|
|
$
|
82,151
|
|
|
$
|
78,217
|
|
Major
line items constituting (loss) income from discontinued operations in the consolidated statements of operations for the three months
ended March 31, 2021 and 2020 consisted of the following (unaudited):
AMSG
& HTS Group (Loss) Income from Discontinued Operations:
|
|
Three Months Ended
|
|
|
|
March 31, 2021
|
|
|
March 31, 2020
|
|
|
|
|
|
|
|
|
Revenue from services**
|
|
$
|
118,216
|
|
|
$
|
159,067
|
|
Cost (recovery) of services
|
|
|
390
|
|
|
|
8,777
|
|
Gross profit
|
|
|
117,826
|
|
|
|
150,290
|
|
Operating expenses
|
|
|
283,500
|
|
|
|
184,368
|
|
Other expense
|
|
|
9,790
|
|
|
|
25,931
|
|
Provision for income taxes
|
|
|
-
|
|
|
|
-
|
|
(Loss) income from discontinued operations
|
|
$
|
(175,464
|
)
|
|
$
|
(60,009
|
)
|
**Revenue
from services, includes related party revenue of $62,316 and $23,400, respectively.
EPIC
Reference Labs, Inc. and Other Subsidiaries (Loss) Income from Discontinued Operations
|
|
Three Months Ended
|
|
|
|
March 31, 2021
|
|
|
March 31, 2020
|
|
|
|
|
|
|
|
|
Revenue from services
|
|
$
|
-
|
|
|
$
|
442
|
|
Cost (recovery) of services (1)
|
|
|
-
|
|
|
|
(110,257
|
)
|
Gross profit
|
|
|
-
|
|
|
|
110,699
|
|
Operating expenses
|
|
|
48,097
|
|
|
|
29,116
|
|
Other expense
|
|
|
3,105
|
|
|
|
2,643
|
|
Provision for income taxes
|
|
|
-
|
|
|
|
-
|
|
(Loss) income from discontinued operations
|
|
$
|
(51,202
|
)
|
|
$
|
78,940
|
|
Consolidated
(Loss) Income from Discontinued Operations:
|
|
Three Months Ended
|
|
|
|
March 31, 2021
|
|
|
March 31, 2020
|
|
|
|
|
|
|
|
|
Revenue from services
|
|
$
|
118,216
|
|
|
$
|
159,509
|
|
Cost (recovery) of services (1)
|
|
|
390
|
|
|
|
(101,480
|
)
|
Gross profit
|
|
|
117,826
|
|
|
|
260,989
|
|
Operating expenses
|
|
|
331,597
|
|
|
|
213,484
|
|
Other expense
|
|
|
12,895
|
|
|
|
28,574
|
|
Provision for income taxes
|
|
|
-
|
|
|
|
-
|
|
(Loss) income from discontinued operations
|
|
$
|
(226,666
|
)
|
|
$
|
18,931
|
|
|
(1)
|
Costs
(recovery) of services in 2020 reflect a reduction of $130,000 in the amount previously recorded for laboratory supplies due to the
settlement of a claim during the period.
|
Note
15 – Recent Accounting Pronouncements
In
August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s
Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. Under this standard customers
will apply the same criteria for capitalizing implementation costs as they would for an arrangement that has a software license. The
adoption of this new guidance prescribes the balance sheet, income statement, and cash flow classification of the capitalized implementation
costs and related amortization expense, and additional quantitative and qualitative disclosures. This ASU became effective for us on
January 1, 2021. The adoption of this ASU did not have a material impact on our results of operations, financial position and cash flows.
In
December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new guidance
simplifies the accounting for income taxes by removing certain exceptions to the general principles and also simplifies areas such as
franchise taxes, step-up in tax basis goodwill, separate entity financial statements and interim recognition of enactment of tax laws
or rate changes. This standard became effective for us on January 1, 2021. The adoption of this ASU did not have a material impact on
our consolidated financial statements.
In
August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40).The new guidance provides accounting for convertible instruments
and contracts in an entity’s own equity. The FASB issued this Update to address issues identified as a result of the complexity
associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. The Board focused
on amending the guidance on convertible instruments and the guidance on the derivatives scope exception for contracts in an entity’s
own equity. This standard will be effective for us for annual periods beginning on January 1, 2024, including interim periods within
those fiscal years. Early adoption of this standard is not permitted for us because we have already adopted ASU 2017-11 “Earnings
Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815).” We have not yet
determined the impact of adopting this new accounting guidance on our consolidated financial statements.
Other
recent accounting standards issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public
Accountants, and the SEC did not or are not believed by management to have a material impact on the Company’s present or future
consolidated financial statements.
Note
16 – Subsequent Events
Conversions
of Series M Preferred Stock and Series N Preferred Stock
Subsequent
to March 31, 2021 and through June 2, 2021, the Company issued 450,000,000 shares of its common stock upon conversions of 619. 65 shares
of its Series M Preferred Stock with a stated value of $0.6 million and 9.1 billion shares of its common stock upon conversions of 8,720.97
shares of its Series N Preferred Stock with a stated value of $8.7 million.
Potential
Common Stock as of June 2, 2021
The
following table presents the dilutive effect of our various potential common shares as of June 2, 2021:
|
|
June 2, 2021
|
|
Common shares outstanding
|
|
|
10.000.000.000
|
|
Dilutive potential shares:
|
|
|
|
|
Stock options
|
|
|
26
|
|
Warrants
|
|
|
89,899,582,113
|
|
Convertible debt
|
|
|
4,408,900,000
|
|
Convertible preferred stock
|
|
|
60,438,595,502
|
|
Total dilutive potential common shares, including outstanding common stock
|
|
|
164,747,077,641
|
|
On
August 13, 2020, Mr. Diamantis entered into the Voting Agreement with the Company, Mr. Lagan and Alcimede (of which Mr. Lagan is the
sole manager) pursuant to which Mr. Diamantis granted an irrevocable proxy to Mr. Lagan to vote the Series M Preferred Stock held by
Mr. Diamantis, Mr. Diamantis has retained all other rights under the Series M Preferred Stock. Regardless of the number of shares of
Series M Preferred Stock outstanding and so long as at least one share of Series M Preferred Stock is outstanding, the outstanding shares
of Series M Preferred Stock shall have the number of votes, in the aggregate, equal to 51% of all votes entitled to be voted at any meeting
of stockholders or action by written consent. This means that the holders of Series M Preferred Stock have sufficient votes, by themselves,
to approve or defeat any proposal voted on by the Company’s stockholders, unless there is a supermajority required under applicable
law or by agreement.
As
a result of the Voting Agreement, as of the date of filing this report, the Company believes that it has the ability to ensure that it
has and or can obtain sufficient authorized shares of its common stock to cover all potentially dilutive common shares outstanding.
Funding
Activities- Warrants Prepayment Promissory Notes
On
April 9, 2021, the Company entered into agreements with certain institutional investors for warrant prepayment promissory notes with
an aggregate principal amount of $165,000. The Company received proceeds of $150,000 from the payees who may at their option apply all
or any portion of the principal amount outstanding to the exercise of any common stock purchase warrants of the Company held by the payee.
The notes are unsecured and they mature 12 months from the date of issuance. The notes do not bear interest but an interest rate of 18%
will be applied to the outstanding principal commencing five days after any event of default that results in the acceleration of the
notes.
On
April 22, 2021, the Company entered into agreements with certain institutional investors for warrant prepayment promissory notes with
an aggregate principal amount of $220,000. The Company received proceeds of $200,000 from the payees who may at their option apply all
or any portion of the principal amount outstanding to the exercise of any common stock purchase warrants of the Company held by the payee.
The notes are unsecured and they mature 12 months from the date of issuance. The notes do not bear interest but an interest rate of 18%
will be applied to the outstanding principal commencing five days after any event of default that results in the acceleration of the
notes.
Funding
Activities – Preferred Stock
On
May 10, 2021, the Company closed an offering of shares of its newly-authorized Series O Convertible Redeemable Preferred Stock (the “Series
O Preferred Stock”). The offering was pursuant to the terms of the Securities Purchase Agreement, dated as of May 10, 2021 (the
“Purchase Agreement”), between the Company and certain existing institutional investors of the Company. The Purchase Agreement
provides for the issuance of up to 4,400 shares of Series O Preferred Stock at four closings of 1,100 shares each. If all such shares
of Series O Preferred Stock are issued, the Company will receive proceeds of $4,000,000.
The
first closing occurred on May 10, 2021 and the second closing occurred on May 18, 2021. The Company issued an aggregate of 2,200 shares
of its Series O Preferred Stock and received total proceeds of $2,000,000 as a result of the first and second closings. The subsequent
closings depend upon the Company’s satisfaction of certain conditions, including effecting certain specified transactions to make
additional shares of common stock available for issuance by the Company. There can be no assurance that the Company will satisfy all
or any of these conditions or that any additional closings will take place. In addition, the Purchase Agreement restricts the Company’s
use of any proceeds of the issuances of the Series O Preferred Stock, including to payroll and tax arrears and legal and accounting expenses.
The
shares of Series O Preferred Stock were issued in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities
Act of 1933, as amended, and by Rule 506 of Regulation D promulgated thereunder as a transaction by an issuer not involving any public
offering.
The
terms of the Series O Preferred Stock were set forth in the Company’s Current Report on Form 8-K filed with the SEC on May 11,
2021, In particular:
General.
The Company’s Board of Directors has designated 10,000 shares of the 5,000,000 authorized shares of preferred stock as the Series
O Preferred Stock. Each share of the Series O Preferred Stock has a stated value of $1,000.
Voting
Rights. Except as provided below or by law, the Series O Preferred Stock shall have no voting rights. However, as long as any shares
of Series O Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the
then outstanding shares of the Series O Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the
Series O Preferred Stock or alter or amend the Certificate of Designation, (b) amend its certificate of incorporation or other charter
documents in any manner that adversely affects any rights of the holders, (c) increase the number of authorized shares of the Series
O Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing.
Dividends.
Dividends at the rate per annum of 10% of the stated value per share shall accrue on each outstanding share of Series O Preferred Stock
from and after the date of the original issuance of such share of Series O Preferred Stock (the “Series O Preferred Accruing Dividends”).
The Series O Preferred Accruing Dividends shall accrue from day to day, whether or not declared, and shall be cumulative and non-compounding;
provided, however, that such Series O Preferred Accruing Dividends shall be payable only when, as, and if declared by the
Board of Directors. No cash dividends shall be paid on the common stock unless the Series O Preferred Accruing Dividends are paid.
Rank.
The Series O Preferred Stock ranks with respect to dividends or a liquidation, (i) on parity with the common stock, the Company’s
Series H Convertible Preferred Stock, the Company’s Series L Convertible Preferred Stock, the Company’s Series M Convertible
Preferred Stock and the Company’s Series N Convertible Preferred Stock, (ii) senior to the Company’s Series F Convertible
Preferred Stock, and (iii) junior to any other class or series of preferred stock of the Company afterwards created and ranking by its
terms senior to the Series O Preferred Stock.
Conversion.
Each share of the Series O Preferred Stock is convertible into shares of the Company’s common stock, at any time and from time
to time, at the option of the holder, into that number of shares of common stock determined by dividing the stated value of such share
of Series O Preferred Stock, plus any accrued declared and unpaid dividends, by the conversion price. The conversion price is equal to
90% of the lowest VWAP during the 10 trading days immediately prior to the conversion date. Holders of the Series O Preferred Stock are
prohibited from converting Series O Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together
with its affiliates, would own more than 9.99% of the total number of shares of common stock then issued and outstanding. However, any
holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage
shall not be effective until 61 days after notice to the Company.
Liquidation
Preference. Upon any liquidation, dissolution or winding up of the Company, the holders of the Series O Preferred Stock shall be
entitled to receive an amount equal to the stated value of the Series O Preferred Stock, plus any accrued declared and unpaid dividends
thereon and any other fees or liquidated damages then due and owing thereon, for each share of the Series O Preferred Stock before any
distribution or payment shall be made on any junior securities.
Redemption.
At any time the Company shall have the right to redeem all, or any part, of the Series O Preferred Stock then outstanding. The Series
O Preferred Stock subject to redemption shall be redeemed by the Company in cash in an amount equal to the stated value of the shares
of the Series O Preferred Stock being redeemed plus all accrued declared and unpaid dividends.
Shareholder
Proposal to Increase Shares of Authorized Common Stock
As
a result of conversions of shares of the Company’s preferred stock, the Company, as of the date of this report, has 10,000,000,000
shares of its common stock issued and outstanding. The Company, therefore, has issued all of its authorized shares of common stock. It
cannot issue additional shares of common stock unless and until it is able to amend its Certificate of Incorporation to increase its
authorized common stock or it effects a reverse stock split. The Company needs immediate additional capital to execute on its business
plan and without the ability to issue shares of common stock will have difficulty securing the capital required to continue in business.
Accordingly, on May 14, 2021, the Company filed a preliminary Information Statement on Schedule 14C to seek approval to effect a reverse
stock split of its common stock. The ratio and timing of the proposed reverse stock split have not yet been determined.
Merger
of AMSG & HTS Group
On
May 13, 2021, Rennova completed an agreement with VisualMED a Nevada based public company, for VisualMED to acquire
AMSG & HTS. After closing these entities will operate as wholly owned subsidiaries of VisualMED. Closing is subject to a
number of customary conditions for a transaction of this nature and was intended to happen on or before May 31, 2021. As part
of the agreement, VisualMED is required to complete any outstanding applications necessary to be fully compliant with
OTC requirements before closing. VisualMED is in process of completing these applications but delayed communication from the
OTC Markets has resulted in the May 31, 2021 timeframe not being met. The Company anticipates that this agreement will close
successfully in the coming weeks. Once the agreement has closed, VisualMED intends to file audited financial statements and
other filings as required to become fully reporting with the SEC.